CDK7
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| O00115 | S70 | Sugiyama | DNASE2 DNASE2A DNL2 | QYKyLDEssGGWRDGRALINsPEGAVGRSLQPLyRSNTSQL |
| O00151 | S90 | Sugiyama | PDLIM1 CLIM1 CLP36 | IKGCTDNLtLtVARsEHKVWsPLVtEEGKRHPYKMNLASEP |
| O00267 | S773 | PSP | SUPT5H SPT5 SPT5H | VGsRRPGGMTsTYGRtPMYGsQtPMYGsGsRtPMYGsQtPL |
| O00267 | S782 | PSP | SUPT5H SPT5 SPT5H | TsTYGRtPMYGsQtPMYGsGsRtPMYGsQtPLQDGsRtPHy |
| O00267 | T775 | PSP | SUPT5H SPT5 SPT5H | sRRPGGMTsTYGRtPMYGsQtPMYGsGsRtPMYGsQtPLQD |
| O00267 | T784 | PSP | SUPT5H SPT5 SPT5H | TYGRtPMYGsQtPMYGsGsRtPMYGsQtPLQDGsRtPHyGs |
| O00311 | S277 | Sugiyama | CDC7 CDC7L1 | KRPYTNAQIQIKQGKDGKEGsVGLsVQRsVFGERNFNIHss |
| O00311 | S281 | Sugiyama | CDC7 CDC7L1 | TNAQIQIKQGKDGKEGsVGLsVQRsVFGERNFNIHssISHE |
| O00311 | S285 | Sugiyama | CDC7 CDC7L1 | IQIKQGKDGKEGsVGLsVQRsVFGERNFNIHssISHEsPAV |
| O14910 | S130 | Sugiyama | LIN7A MALS1 VELI1 | ELPKTDEGLGFNVMGGKEQNsPIyIsRIIPGGVAERHGGLK |
| O43707 | T429 | Sugiyama | ACTN4 | ERLDHLAEKFRQKAsIHEAWtDGKEAMLKHRDyEtAtLsDI |
| O43852 | S261 | Sugiyama | CALU | RDKNRDGKMDKEEtKDWILPsDyDHAEAEARHLVyEsDQNK |
| O60841 | S182 | Sugiyama | EIF5B IF2 KIAA0741 | DGsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKK |
| O75821 | S28 | Sugiyama | EIF3G EIF3S4 | sKPsWADQVEEEGEDDKCVtsELLKGIPLAtGDtsPEPELL |
| O75821 | T27 | Sugiyama | EIF3G EIF3S4 | DsKPsWADQVEEEGEDDKCVtsELLKGIPLAtGDtsPEPEL |
| P02545 | T19 | Sugiyama | LMNA LMN1 | __METPsQRRAtRsGAQAsstPLsPtRItRLQEKEDLQELN |
| P03372 | S118 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | ESR1 ESR NR3A1 | PPLNsVsPsPLMLLHPPPQLsPFLQPHGQQVPYYLENEPSG |
| P04083 | S189 | Sugiyama | ANXA1 ANX1 LPC1 | tsDtsGDFRNALLsLAKGDRsEDFGVNEDLADsDARALyEA |
| P04637 | S33 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | TP53 P53 | PLsQEtFsDLWKLLPENNVLsPLPsQAMDDLMLsPDDIEQW |
| P04637 | S371 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | TP53 P53 | KDAQAGKEPGGSRAHssHLKsKKGQstsRHKKLMFKtEGPD |
| P04637 | S376 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | TP53 P53 | GKEPGGSRAHssHLKsKKGQstsRHKKLMFKtEGPDsD___ |
| P04637 | S378 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | TP53 P53 | EPGGSRAHssHLKsKKGQstsRHKKLMFKtEGPDsD_____ |
| P04637 | S392 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | TP53 P53 | KKGQstsRHKKLMFKtEGPDsD___________________ |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P05187 | S177 | Sugiyama | ALPP PLAP | RAKKAGKSVGVVTTTRVQHAsPAGtyAHtVNRNWysDADVP |
| P05386 | S101 | Sugiyama | RPLP1 RRP1 | APstAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD_______ |
| P05386 | S104 | Sugiyama | RPLP1 RRP1 | tAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S102 | Sugiyama | RPLP2 D11S2243E RPP2 | PAAGsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD_______ |
| P05387 | S105 | Sugiyama | RPLP2 D11S2243E RPP2 | GsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD__________ |
| P05388 | S304 | Sugiyama | RPLP0 | AttAAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD_______ |
| P05388 | S307 | Sugiyama | RPLP0 | AAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD__________ |
| P06400 | S780 | PSP | RB1 | FMQRLKtNILQyAstRPPtLsPIPHIPRsPyKFPssPLRIP |
| P06400 | S807 | PSP | RB1 | RsPyKFPssPLRIPGGNIyIsPLKsPYKIsEGLPtPtKMtP |
| P06400 | S811 | PSP | RB1 | KFPssPLRIPGGNIyIsPLKsPYKIsEGLPtPtKMtPRSRI |
| P06493 | T161 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | CDK1 CDC2 CDC28A CDKN1 P34CDC2 | tIKLADFGLARAFGIPIRVytHEVVTLWYRSPEVLLGsARY |
| P07237 | S88 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GKLKAEGSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNG |
| P07237 | T85 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | KAAGKLKAEGSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFF |
| P07237 | Y94 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | GSEIRLAKVDAtEEsDLAQQyGVRGyPtIKFFRNGDTASPK |
| P08708 | S89 | Sugiyama | RPS17 RPS17L | ISIKLQEEERERRDNyVPEVsALDQEIIEVDPDtKEMLKLL |
| P09923 | S174 | Sugiyama | ALPI | RAKQAGKSVGVVTTTRVQHAsPAGtyAHtVNRNWysDADMP |
| P10275 | S516 | SIGNOR|EPSD|PSP | AR DHTR NR3C4 | DFTAPDVWYPGGMVSRVPYPsPTCVKSEMGPWMDSYSGPyG |
| P10276 | S77 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | RARA NR1B1 | SPATIETQSSSSEEIVPsPPsPPPLPRIYKPCFVCQDKSsG |
| P10412 | S41 | Sugiyama | H1-4 H1F4 HIST1H1E | KKKARKsAGAAKRKAsGPPVsELItKAVAASKERsGVsLAA |
| P10809 | S70 | Sugiyama | HSPD1 HSP60 | AVAVTMGPKGRtVIIEQsWGsPKVTKDGVtVAKsIDLKDKY |
| P11021 | T69 | PSP | HSPA5 GRP78 | RVEIIANDQGNRItPSYVAFtPEGERLIGDAAKNQLtsNPE |
| P11802 | T172 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | CDK4 | GTVKLADFGLARIYSYQMALtPVVVTLWYRAPEVLLQSTYA |
| P12270 | S2155 | Sugiyama | TPR | PstPtLVVPHRtDGFAEAIHsPQVAGVPRFRFGPPEDMPQT |
| P12814 | T410 | Sugiyama | ACTN1 | ERLDHLAEKFRQKAsIHEAWtDGKEAMLRQKDyEtAtLsEI |
| P13631 | S77 | SIGNOR|EPSD|PSP | RARG NR1B3 | EMASLSVETQSTSSEEMVPSsPsPPPPPRVYKPCFVCNDKS |
| P13631 | S79 | SIGNOR|EPSD|PSP | RARG NR1B3 | ASLSVETQSTSSEEMVPSsPsPPPPPRVYKPCFVCNDKSSG |
| P13639 | S595 | Sugiyama | EEF2 EF2 | PVVsyREtVsEEsNVLCLsKsPNKHNRLyMKARPFPDGLAE |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P14649 | S87 | Sugiyama | MYL6B MLC1SA | EEFKEAFELFDRVGDGKILysQCGDVMRALGQNPtNAEVLK |
| P14859 | S385 | GPS6|ELM|iPTMNet|EPSD | POU2F1 OCT1 OTF1 | PsALNsPGIEGLSRRRKKRtsIETNIRVALEKSFLENQKPT |
| P14866 | S101 | Sugiyama | HNRNPL HNRPL P/OKcl.14 | GAAGGGGGGENyDDPHKtPAsPVVHIRGLIDGVVEADLVEA |
| P15311 | S535 | Sugiyama | EZR VIL2 | EKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHN |
| P15531 | S120 | Sugiyama | NME1 NDPKA NM23 | KPGtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELV |
| P16402 | S42 | Sugiyama | H1-3 H1F3 HIST1H1D | KKAKKAGATAGKRKAsGPPVsELItKAVAASKERsGVsLAA |
| P16403 | S41 | Sugiyama | H1-2 H1F2 HIST1H1C | KKKAAKKAGGtPRKAsGPPVsELItKAVAASKERsGVsLAA |
| P17812 | S575 | Sugiyama | CTPS1 CTPS | LQKGCRLsPRDtysDRsGsssPDsEItELKFPsINHD____ |
| P17987 | S551 | Sugiyama | TCP1 CCT1 CCTA | IKLHPESKDDKHGsyEDAVHsGALND_______________ |
| P18583 | S152 | Sugiyama | SON C21orf50 DBP5 KIAA1019 NREBP HSPC310 HSPC312 | QPEESESKtKsHDDGNIDLEsDsFLKFDsEPsAVALELPTR |
| P18583 | S154 | Sugiyama | SON C21orf50 DBP5 KIAA1019 NREBP HSPC310 HSPC312 | EESESKtKsHDDGNIDLEsDsFLKFDsEPsAVALELPTRAF |
| P18615 | S138 | Sugiyama | NELFE RD RDBP | DDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEAEGPGA |
| P18615 | S140 | Sugiyama | NELFE RD RDBP | LQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEAEGPGAGD |
| P18669 | S31 | Sugiyama | PGAM1 PGAMA CDABP0006 | HGEsAWNLENRFsGWyDADLsPAGHEEAKRGGQALRDAGyE |
| P19447 | S90 | SIGNOR|PSP | ERCC3 XPB XPBC | DHTSRPLWVAPDGHIFLEAFsPVYKYAQDFLVAIAEPVCRP |
| P20042 | S67 | Sugiyama | EIF2S2 EIF2B | EPtEDKDLEADEEDTRKKDAsDDLDDLNFFNQKKKKKKTKK |
| P20700 | S23 | Sugiyama | LMNB1 LMN2 LMNB | TAtPVPPRMGsRAGGPttPLsPtRLsRLQEKEELRELNDRL |
| P21127 | S482 | GPS6|EPSD | CDK11B CDC2L1 CDK11 PITSLREA PK58 | EIVALKRLKMEKEKEGFPITsLREINtILKAQHPNIVTVRE |
| P21127 | T488 | GPS6|EPSD | CDK11B CDC2L1 CDK11 PITSLREA PK58 | RLKMEKEKEGFPITsLREINtILKAQHPNIVTVREIVVGSN |
| P21127 | T595 | SIGNOR|EPSD|PSP | CDK11B CDC2L1 CDK11 PITSLREA PK58 | ILKVGDFGLAREyGsPLKAytPVVVtLWYRAPELLLGAKEY |
| P22234 | S27 | Sugiyama | PAICS ADE2 AIRC PAIS | LNIGKKLYEGKtKEVyELLDsPGKVLLQsKDQItAGNAARK |
| P22626 | S259 | Sugiyama | HNRNPA2B1 HNRPA2B1 | GFGDGyNGyGGGPGGGNFGGsPGyGGGRGGYGGGGPGYGNQ |
| P23434 | S153 | Sugiyama | GCSH | LVNKSCyEDGWLIKMtLsNPsELDELMsEEAyEKYIKSIEE |
| P23588 | T205 | Sugiyama | EIF4B | GRDRNRDsDKtDTDWRARPAtDsFDDyPPRRGDDsFGDKYR |
| P24928 | S1616 | EPSD|PSP | POLR2A POLR2 | TSPAYEPRSPGGYTPQSPSysPtsPsYsPTsPSYSPTSPNY |
| P24928 | S1619 | SIGNOR|EPSD|PSP | POLR2A POLR2 | AYEPRSPGGYTPQSPSysPtsPsYsPTsPSYSPTSPNYSPT |
| P24928 | S1621 | EPSD|PSP | POLR2A POLR2 | EPRSPGGYTPQSPSysPtsPsYsPTsPSYSPTSPNYSPTSP |
| P24928 | S1626 | SIGNOR | POLR2A POLR2 | GGYTPQSPSysPtsPsYsPTsPSYSPTSPNYSPTSPSYsPT |
| P24928 | S1647 | SIGNOR | POLR2A POLR2 | PSYSPTSPNYSPTSPSYsPTsPSYsPTsPSYSPTSPSYsPT |
| P24928 | S1654 | SIGNOR | POLR2A POLR2 | PNYSPTSPSYsPTsPSYsPTsPSYSPTSPSYsPTsPSYsPT |
| P24928 | S1668 | SIGNOR | POLR2A POLR2 | PSYsPTsPSYSPTSPSYsPTsPSYsPTsPSYSPTSPSYSPT |
| P24928 | S1675 | SIGNOR | POLR2A POLR2 | PSYSPTSPSYsPTsPSYsPTsPSYSPTSPSYSPTSPSYsPT |
| P24928 | S1696 | SIGNOR | POLR2A POLR2 | PSYSPTSPSYSPTSPSYsPTsPSYSPTSPSYSPTSPSYsPT |
| P24928 | S1717 | SIGNOR | POLR2A POLR2 | PSYSPTSPSYSPTSPSYsPTsPSYsPTsPSYSPTSPSYsPT |
| P24928 | S1724 | SIGNOR | POLR2A POLR2 | PSYSPTSPSYsPTsPSYsPTsPSYSPTSPSYsPTsPSYSPT |
| P24928 | S1738 | SIGNOR | POLR2A POLR2 | PSYsPTsPSYSPTSPSYsPTsPSYSPTSPNYSPTSPNYTPT |
| P24928 | S1766 | SIGNOR | POLR2A POLR2 | PNYSPTSPNYTPTSPSYsPTsPSYSPTSPNYTPTSPNYsPT |
| P24928 | S1787 | SIGNOR | POLR2A POLR2 | PSYSPTSPNYTPTSPNYsPTsPSYSPTSPSYSPTSPSYSPS |
| P24928 | S1864 | SIGNOR | POLR2A POLR2 | PsysPssPEytPtsPKysPtsPKysPtsPKysPtsPtysPt |
| P24928 | S1871 | SIGNOR | POLR2A POLR2 | PEytPtsPKysPtsPKysPtsPKysPtsPtysPttPKysPt |
| P24928 | S1878 | EPSD|PSP | POLR2A POLR2 | PKysPtsPKysPtsPKysPtsPtysPttPKysPtsPtysPt |
| P24928 | S1882 | SIGNOR | POLR2A POLR2 | PtsPKysPtsPKysPtsPtysPttPKysPtsPtysPtsPVy |
| P24928 | S1892 | SIGNOR | POLR2A POLR2 | PKysPtsPtysPttPKysPtsPtysPtsPVytPtsPKysPt |
| P24928 | S1899 | SIGNOR | POLR2A POLR2 | PtysPttPKysPtsPtysPtsPVytPtsPKysPtsPtysPt |
| P24928 | S1913 | SIGNOR | POLR2A POLR2 | PtysPtsPVytPtsPKysPtsPtysPtsPKysPtsPtysPt |
| P24928 | S1920 | SIGNOR|Sugiyama | POLR2A POLR2 | PVytPtsPKysPtsPtysPtsPKysPtsPtysPtsPKGstY |
| P24928 | S1927 | SIGNOR | POLR2A POLR2 | PKysPtsPtysPtsPKysPtsPtysPtsPKGstYsPtsPGY |
| P24928 | S1934 | SIGNOR | POLR2A POLR2 | PtysPtsPKysPtsPtysPtsPKGstYsPtsPGYsPtsPTY |
| P24928 | S1944 | SIGNOR | POLR2A POLR2 | sPtsPtysPtsPKGstYsPtsPGYsPtsPTYSLTsPAIsPD |
| P24928 | S1951 | SIGNOR | POLR2A POLR2 | sPtsPKGstYsPtsPGYsPtsPTYSLTsPAIsPDDsDEEN_ |
| P24928 | T1919 | Sugiyama | POLR2A POLR2 | sPVytPtsPKysPtsPtysPtsPKysPtsPtysPtsPKGst |
| P24928 | Y1909 | Sugiyama | POLR2A POLR2 | sPtsPtysPtsPVytPtsPKysPtsPtysPtsPKysPtsPt |
| P24941 | S46 | EPSD|PSP | CDK2 CDKN2 | TGEVVALKKIRLDtETEGVPstAIREIsLLKELNHPNIVKL |
| P24941 | T160 | GPS6|SIGNOR|iPTMNet|EPSD|PSP | CDK2 CDKN2 | AIKLADFGLARAFGVPVRtytHEVVtLWyRAPEILLGCKYY |
| P24941 | T165 | EPSD|PSP | CDK2 CDKN2 | DFGLARAFGVPVRtytHEVVtLWyRAPEILLGCKYYSTAVD |
| P24941 | Y168 | EPSD|PSP | CDK2 CDKN2 | LARAFGVPVRtytHEVVtLWyRAPEILLGCKYYSTAVDIWS |
| P25786 | S14 | Sugiyama | PSMA1 HC2 NU PROS30 PSC2 | _______MFRNQyDNDVtVWsPQGRIHQIEYAMEAVKQGSA |
| P26038 | S527 | Sugiyama | MSN | ERTTEAEKNERVQKHLKALtsELANARDEsKKTANDMIHAE |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P26038 | T526 | Sugiyama | MSN | EERTTEAEKNERVQKHLKALtsELANARDEsKKTANDMIHA |
| P26196 | S475 | Sugiyama | DDX6 HLR2 RCK | TEIKPIPsNIDKSLyVAEyHsEPVEDEKP____________ |
| P26885 | S108 | Sugiyama | FKBP2 FKBP13 | GWDQGLLGMCEGEKRKLVIPsELGyGERGAPPKIPGGATLV |
| P27348 | S45 | Sugiyama | YWHAQ | CMKAVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSI |
| P27797 | S52 | Sugiyama | CALR CRTC | GWtsRWIEsKHKSDFGKFVLssGKFyGDEEKDKGLQTSQDA |
| P27797 | T34 | Sugiyama | CALR CRTC | LAVAEPAVYFKEQFLDGDGWtsRWIEsKHKSDFGKFVLssG |
| P27824 | S583 | Sugiyama | CANX | VsQEEEDRKPKAEEDEILNRsPRNRKPRRE___________ |
| P29474 | S1177 | GPS6 | NOS3 | EDIFGLTLRTQEVTSRIRtQsFsLQERQLRGAVPWAFDPPG |
| P29474 | S633 | GPS6 | NOS3 | FNsISCSDPLVssWRRKRKEssNtDSAGALGTLRFCVFGLG |
| P29692 | S162 | Sugiyama | EEF1D EF1D | AKKPAtPAEDDEDDDIDLFGsDNEEEDKEAAQLREERLRQY |
| P30086 | S104 | Sugiyama | PEBP1 PBP PEBP | WHHFLVVNMKGNDIssGtVLsDyVGsGPPKGtGLHRyVWLV |
| P31946 | S47 | Sugiyama | YWHAB | AMKAVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P31947 | S45 | Sugiyama | SFN HME1 | FMKGAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsI |
| P32969 | S182 | Sugiyama | RPL9 OK/SW-cl.103; RPL9P7; RPL9P8; RPL9P9 | QQATTVKNKDIRKFLDGIyVsEKGtVQQADE__________ |
| P35241 | S532 | Sugiyama | RDX | EERVTETQKNERVKKQLQALssELAQARDETKKTQNDVLHA |
| P35241 | S533 | Sugiyama | RDX | ERVTETQKNERVKKQLQALssELAQARDETKKTQNDVLHAE |
| P35579 | T1904 | Sugiyama | MYH9 | EEAQRANAsRRKLQRELEDAtEtADAMNREVssLKNKLRRG |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46776 | S139 | Sugiyama | RPL27A | KQPVIVKAKFFSRRAEEKIKsVGGACVLVA___________ |
| P46777 | S172 | Sugiyama | RPL5 MSTP030 | RTTTGNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNA |
| P46777 | S176 | Sugiyama | RPL5 MSTP030 | GNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHR |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46777 | T177 | Sugiyama | RPL5 MSTP030 | NKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHRK |
| P46783 | S146 | Sugiyama | RPS10 | TYRRSAVPPGADKKAEAGAGsAtEFQFRGGFGRGRGQPPQ_ |
| P49736 | S108 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | DAYEAEGLALDDEDVEELtAsQREAAERAMRQRDREAGRGL |
| P49736 | S13 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | ________MAEssEsFtMAssPAQRRRGNDPLtssPGRssR |
| P49736 | S139 | SIGNOR|EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | QRDREAGRGLGRMRRGLLyDsDEEDEERPARKRRQVERAtE |
| P49736 | S27 | SIGNOR|EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | sFtMAssPAQRRRGNDPLtssPGRssRRtDALtssPGRDLP |
| P49736 | S4 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | _________________MAEssEsFtMAssPAQRRRGNDPL |
| P49736 | S40 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | GNDPLtssPGRssRRtDALtssPGRDLPPFEDEsEGLLGtE |
| P49736 | S41 | SIGNOR|EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | NDPLtssPGRssRRtDALtssPGRDLPPFEDEsEGLLGtEG |
| P49736 | S5 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | ________________MAEssEsFtMAssPAQRRRGNDPLt |
| P49736 | S53 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | RRtDALtssPGRDLPPFEDEsEGLLGtEGPLEEEEDGEELI |
| P49736 | S7 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | ______________MAEssEsFtMAssPAQRRRGNDPLtss |
| P49736 | T59 | EPSD|PSP | MCM2 BM28 CCNL1 CDCL1 KIAA0030 | tssPGRDLPPFEDEsEGLLGtEGPLEEEEDGEELIGDGMER |
| P49840 | Y279 | Sugiyama | GSK3A | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P49841 | Y216 | Sugiyama | GSK3B | LKLCDFGSAKQLVRGEPNVsyICsRYYRAPELIFGATDYTS |
| P50613 | S164 | GPS6|ELM|iPTMNet|EPSD|Sugiyama | CDK7 CAK CAK1 CDKN7 MO15 STK1 | LLDENGVLKLADFGLAKsFGsPNRAytHQVVtRWYRAPELL |
| P50613 | S321 | Sugiyama | CDK7 CAK CAK1 CDKN7 MO15 STK1 | PtPGCQLPRPNCPVETLKEQsNPALAIKRKRTEALEQGGLP |
| P50613 | T170 | GPS6|ELM|iPTMNet|EPSD|Sugiyama | CDK7 CAK CAK1 CDKN7 MO15 STK1 | VLKLADFGLAKsFGsPNRAytHQVVtRWYRAPELLFGARMY |
| P50613 | Y169 | Sugiyama | CDK7 CAK CAK1 CDKN7 MO15 STK1 | GVLKLADFGLAKsFGsPNRAytHQVVtRWYRAPELLFGARM |
| P50750 | S175 | EPSD|PSP | CDK9 CDC2L4 TAK | VLITRDGVLKLADFGLARAFsLAKNSQPNRytNRVVTLWYR |
| P51946 | S322 | Sugiyama | CCNH | YVsKKSKHEEEEWtDDDLVEsL___________________ |
| P51946 | T315 | Sugiyama | CCNH | KGYEDDDYVsKKSKHEEEEWtDDDLVEsL____________ |
| P51948 | S279 | Sugiyama | MNAT1 CAP35 MAT1 RNF66 | HVPELEMLGRLGYLNHVRAAsPQDLAGGYTSSLACHRALQD |
| P51948 | T67 | Sugiyama | MNAT1 CAP35 MAT1 RNF66 | PECGtPLRKSNFRVQLFEDPtVDKEVEIRKKVLKIYNKREE |
| P53999 | S118 | Sugiyama | SUB1 PC4 RPO2TC1 | PGRKGIsLNPEQWsQLKEQIsDIDDAVRKL___________ |
| P60660 | S30 | Sugiyama | MYL6 | AEFKEAFQLFDRtGDGKILysQCGDVMRALGQNPtNAEVLK |
| P61247 | S236 | Sugiyama | RPS3A FTE1 MFTL | KMLKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGy |
| P61978 | S284 | Sugiyama | HNRNPK HNRPK | MPPGRGGRPMPPSRRDyDDMsPRRGPPPPPPGRGGRGGsRA |
| P61978 | Y72 | Sugiyama | HNRNPK HNRPK | KNAGAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsISA |
| P61981 | S46 | Sugiyama | YWHAG | AMKNVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S46 | Sugiyama | YWHAE | SMKKVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssI |
| P62263 | T133 | Sugiyama | RPS14 PRO2640 | QsALRALARSGMKIGRIEDVtPIPsDstRRKGGRRGRRL__ |
| P62424 | T84 | Sugiyama | RPL7A SURF-3 SURF3 | QRQRAILyKRLKVPPAINQFtQALDRQTAtQLLKLAHKYRP |
| P62942 | S9 | Sugiyama | FKBP1A FKBP1 FKBP12 | ____________MGVQVEtIsPGDGRtFPKRGQtCVVHytG |
| P62979 | S123 | Sugiyama | RPS27A UBA80 UBCEP1 | LKYYKVDENGKIsRLRRECPsDECGAGVFMAsHFDRHyCGK |
| P62979 | S134 | Sugiyama | RPS27A UBA80 UBCEP1 | IsRLRRECPsDECGAGVFMAsHFDRHyCGKCCLtyCFNKPE |
| P63104 | S45 | Sugiyama | YWHAZ | CMKsVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssI |
| P68363 | S439 | Sugiyama | TUBA1B | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| Q00534 | T177 | EPSD|PSP | CDK6 CDKN6 | GQIKLADFGLARIYSFQMALtSVVVTLWYRAPEVLLQSSYA |
| Q01094 | S403 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | E2F1 RBBP3 | LLEHVREDFSGLLPEEFISLsPPHEALDYHFGLEEGEGIRD |
| Q01094 | T433 | GPS6|SIGNOR|ELM|iPTMNet|EPSD|PSP | E2F1 RBBP3 | FGLEEGEGIRDLFDCDFGDLtPLDF________________ |
| Q01130 | S208 | Sugiyama | SRSF2 SFRS2 | RsRsPPPVsKRESKSRSRsKsPPKsPEEEGAVss_______ |
| Q01860 | S12 | SIGNOR|PSP | POU5F1 OCT3 OCT4 OTF3 | _________MAGHLASDFAFsPPPGGGGDGPGGPEPGWVDP |
| Q04917 | S46 | Sugiyama | YWHAH YWHA1 | AMKAVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSI |
| Q07021 | S213 | Sugiyama | C1QBP GC1QBP HABP1 SF2P32 | VGQEDEAEsDIFsIREVsFQstGESEWKDTNYTLNTDSLDW |
| Q07960 | S50 | Sugiyama | ARHGAP1 CDC42GAP RHOGAP1 | EKNWPsDEMPDFPKsDDsKsssPELVtHLKWDDPyyDIARH |
| Q09028 | S147 | Sugiyama | RBBP4 RBAP48 | VNRARYMPQNPCIIATKtPssDVLVFDyTKHPsKPDPsGEC |
| Q13283 | S231 | Sugiyama | G3BP1 G3BP | QEEKPEPVLEETAPEDAQKsssPAPADIAQtVQEDLRtFsW |
| Q13283 | S232 | Sugiyama | G3BP1 G3BP | EEKPEPVLEETAPEDAQKsssPAPADIAQtVQEDLRtFsWA |
| Q13285 | S203 | GPS6|SIGNOR|EPSD|PSP | NR5A1 AD4BP FTZF1 SF1 | YLYPAFPGRAIKSEYPEPYAsPPQPGLPYGYPEPFSGGPNV |
| Q14103 | S190 | Sugiyama | HNRNPD AUF1 HNRPD | KRAKAMKTKEPVKKIFVGGLsPDtPEEKIREYFGGFGEVES |
| Q14247 | S405 | Sugiyama | CTTN EMS1 | EEARRKLEEQARAKtQtPPVsPAPQPtEERLPssPVyEDAA |
| Q14257 | S298 | Sugiyama | RCN2 ERC55 | NGDKKLsEEEILENPDLFLtsEAtDyGRQLHDDyFyHDEL_ |
| Q14847 | S146 | GPS6|ELM|iPTMNet|EPSD | LASP1 MLN50 | FEKSRMGPsGGEGMEPERRDsQDGssyRRPLEQQQPHHIPt |
| Q15185 | S113 | Sugiyama | PTGES3 P23 TEBP | RAKLNWLsVDFNNWKDWEDDsDEDMsNFDRFSEMMNNMGGD |
| Q15293 | T76 | Sugiyama | RCN1 RCN | FQYDHEAFLGKEDsKtFDQLtPDEsKERLGKIVDRIDNDGD |
| Q15648 | T1457 | PSP | MED1 ARC205 CRSP1 CRSP200 DRIP205 DRIP230 PBP PPARBP PPARGBP RB18A TRAP220 TRIP2 | sGstPKHERGsPsHsKsPAytPQNLDsEsEsGSSIAEKsyQ |
| Q15797 | S206 | EPSD|PSP | SMAD1 BSP1 MADH1 MADR1 | HsPNSSYPNsPGSSSStYPHsPTSSDPGsPFQMPADTPPPA |
| Q16576 | S146 | Sugiyama | RBBP7 RBAP46 | VNRARYMPQNPHIIATKtPssDVLVFDyTKHPAKPDPsGEC |
| Q6PKG0 | S627 | Sugiyama | LARP1 KIAA0731 LARP | FLFDEEMEQMDGRKNtFtAWsDEEsDyEIDDRDVNKILIVt |
| Q6PKG0 | S631 | Sugiyama | LARP1 KIAA0731 LARP | EEMEQMDGRKNtFtAWsDEEsDyEIDDRDVNKILIVtQtPH |
| Q6PKG0 | S774 | Sugiyama | LARP1 KIAA0731 LARP | LFGAPEPstIARsLPttVPEsPNyRNtRtPRtPRtPQLKDS |
| Q6PKG0 | Y633 | Sugiyama | LARP1 KIAA0731 LARP | MEQMDGRKNtFtAWsDEEsDyEIDDRDVNKILIVtQtPHyM |
| Q71U36 | S439 | Sugiyama | TUBA1A TUBA3 | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| Q7Z417 | S692 | Sugiyama | NUFIP2 KIAA1321 PIG1 | IWNLQKQDPKRIItyNEAMDsPDQ_________________ |
| Q8N543 | S256 | PSP | OGFOD1 KIAA1612 TPA1 | WFHGPSLTRPPNYFEPPIPRsPHIPQDHEILYDWINPTYLD |
| Q8NBJ5 | S612 | Sugiyama | COLGALT1 GLT25D1 PSEC0241 | QKMREQQALSREAKNsDVLQsPLDsAARDEL__________ |
| Q8NHW5 | S304 | Sugiyama | RPLP0P6 | DTTAAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD_______ |
| Q8NHW5 | S307 | Sugiyama | RPLP0P6 | AAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD__________ |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q8TC07 | S675 | Sugiyama | TBC1D15 | TSAFQSNALPTLSASGARNDsPtQIPVssDVCRLtPA____ |
| Q96C19 | S74 | Sugiyama | EFHD2 SWS1 | ELSAKLLRRADLNQGIGEPQsPsRRVFNPytEFKEFSRKQI |
| Q99614 | S89 | Sugiyama | TTC1 TPR1 | sFEEEPGADKVENKsNEDVNssELDEEyLIELEKNMSDEEK |
| Q99614 | S90 | Sugiyama | TTC1 TPR1 | FEEEPGADKVENKsNEDVNssELDEEyLIELEKNMSDEEKQ |
| Q9BQE3 | S439 | Sugiyama | TUBA1C TUBA6 | SEAREDMAALEKDyEEVGADsADGEDEGEEy__________ |
| Q9BYE7 | S30 | SIGNOR|iPTMNet|EPSD|PSP | PCGF6 MBLR RNF134 | GSVGAAKTEGAAALPPPPPVsPPALTPAPAAGEEGPAPLSE |
| Q9C0C2 | S1103 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | KRGWVGEFSLSVGPQREAAFsPGQQDWsRDFCIEASERsyQ |
| Q9H0B6 | S445 | Sugiyama | KLC2 | RRDsAPyGEyGsWYKACKVDsPtVNTTLRSLGALYRRQGKL |
| Q9H0D6 | T439 | SIGNOR|EPSD|PSP | XRN2 | KEKRKRMKRDQPAFtPsGILtPHALGsRNsPGsQVAsNPRQ |
| Q9H1E3 | S113 | Sugiyama | NUCKS1 NUCKS JC7 | RQAASKAASKQREMLMEDVGsEEEQEEEDEAPFQEKDsGsD |
| Q9H4A3 | S1261 | Sugiyama | WNK1 HSN2 KDP KIAA0344 PRKWNK1 | GIPTSSLTQVVHSAGRRFIVsPVPEsRLRESKVFPSEITDT |
| Q9H773 | S85 | Sugiyama | DCTPP1 XTP3TPA CDA03 | GELAELFQWKTDGEPGPQGWsPRERAALQEELSDVLIYLVA |
| Q9HAP6 | S115 | Sugiyama | LIN7B MALS2 VELI2 UNQ3116/PRO10200 | ELPKTDEGLGFNIMGGKEQNsPIyIsRVIPGGVADRHGGLK |
| Q9NQ39 | S157 | Sugiyama | RPS10P5 RPS10L | TYRRCSVPPGADKKAEAGAGsAtEFQFRGRCGRGRGQPPQ_ |
| Q9NUP9 | S115 | Sugiyama | LIN7C MALS3 VELI3 | ELPKTEEGLGFNIMGGKEQNsPIyIsRIIPGGIADRHGGLK |
| Q9NUQ3 | S97 | Sugiyama | TXLNG CXorf15 ELRG LSR5 | KHSLEEDEGsDFItENRNLVsPAyCtQEsREEIPGGEARTD |
| Q9NYV4 | T893 | SIGNOR|EPSD|PSP | CDK12 CRK7 CRKRS KIAA0904 | IKLADFGLARLYNsEEsRPYtNKVITLWYRPPELLLGEERY |
| Q9NZB2 | T991 | Sugiyama | FAM120A C9orf10 KIAA0183 OSSA | PLQVVSVGGPARGRPRGVIstPVIRTFGRGGRYYGRGYKNQ |
| Q9UBU7 | S282 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | QKQTQVKLRIQtDGDKYGGtsIQLQLKEKKKKGYCECCLQK |
| Q9UBU7 | S312 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | KKGYCECCLQKYEDLEtHLLsEQHRNFAQSNQYQVVDDIVS |
| Q9UBU7 | S508 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | ASVHVSDFSTDNSGsQPKQKsDtVLFPAKDLKEKDLHSIFT |
| Q9UBU7 | T281 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | MQKQTQVKLRIQtDGDKYGGtsIQLQLKEKKKKGYCECCLQ |
| Q9UBU7 | T308 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | KEKKKKGYCECCLQKYEDLEtHLLsEQHRNFAQSNQYQVVD |
| Q9UBU7 | T390 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | EQKEKVELQHIsQKDCQEDDttVKEQNFLYKETQETEKKLL |
| Q9UBU7 | T391 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | QKEKVELQHIsQKDCQEDDttVKEQNFLYKETQETEKKLLF |
| Q9UBU7 | T510 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | VHVSDFSTDNSGsQPKQKsDtVLFPAKDLKEKDLHSIFTHD |
| Q9UBU7 | T553 | Sugiyama | DBF4 ASK DBF4A ZDBF1 | LITINSsQEHLTVQAKAPFHtPPEEPNECDFKNMDSLPsGK |
| Q9UPR0 | T584 | Sugiyama | PLCL2 KIAA1092 PLCE2 | KILIKAKKLsSNCSGVEGDVtDEDEGAEMSQRMGKENMEQP |
| Q9UPZ9 | T157 | GPS6|ELM|iPTMNet|EPSD | CILK1 ICK KIAA0936 | ELVKIADFGLAREIRSKPPYtDyVsTRWYRAPEVLLRSTNY |
| Q9UQ35 | S2398 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | ANLtsPRVPLsAyERVsGRtsPPLLDRARsRtPPsAPsQsR |
| Q9Y2B0 | S115 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | QIDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKF |
| Q9Y2B0 | S116 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | IDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKFA |
| Q9Y2B0 | S65 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | VDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLEEI |
| Q9Y2W1 | S240 | Sugiyama | THRAP3 BCLAF2 TRAP150 | sKPWPDAtyGtGsAsRAsAVsELsPRERsPALKsPLQsVVV |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Chromatin organization | R-HSA-4839726 | 0.000001 | 5.925 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.000004 | 5.396 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.000007 | 5.128 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.000007 | 5.133 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.000054 | 4.271 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.000058 | 4.234 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.000085 | 4.073 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.000114 | 3.941 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.000131 | 3.882 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.000177 | 3.753 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.000227 | 3.643 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.000247 | 3.608 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.000388 | 3.411 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.000484 | 3.315 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.000654 | 3.184 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.000688 | 3.162 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 0.000859 | 3.066 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.001063 | 2.973 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.001118 | 2.951 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.001640 | 2.785 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.001621 | 2.790 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.001594 | 2.798 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.001825 | 2.739 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.001838 | 2.736 | 1 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.001941 | 2.712 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.002108 | 2.676 | 1 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.002410 | 2.618 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.002604 | 2.584 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.002514 | 2.600 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.002501 | 2.602 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.002825 | 2.549 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.002825 | 2.549 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.003250 | 2.488 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.003188 | 2.496 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.003188 | 2.496 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.003057 | 2.515 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.003094 | 2.510 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.003368 | 2.473 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.003377 | 2.471 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.003436 | 2.464 | 1 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.003692 | 2.433 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.003692 | 2.433 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.003692 | 2.433 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.003608 | 2.443 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.003962 | 2.402 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.003975 | 2.401 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.003975 | 2.401 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.004428 | 2.354 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.005006 | 2.301 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.005473 | 2.262 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.005596 | 2.252 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.005811 | 2.236 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.005811 | 2.236 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.006123 | 2.213 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 0.006123 | 2.213 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.006643 | 2.178 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.006950 | 2.158 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.007516 | 2.124 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.008632 | 2.064 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.008623 | 2.064 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.008932 | 2.049 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.008719 | 2.060 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.008623 | 2.064 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.008623 | 2.064 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.007977 | 2.098 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.008623 | 2.064 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.009808 | 2.008 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.010046 | 1.998 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.010120 | 1.995 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 0.010687 | 1.971 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.011114 | 1.954 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.012635 | 1.898 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.012635 | 1.898 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.012635 | 1.898 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.012635 | 1.898 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.012635 | 1.898 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.012635 | 1.898 | 0 | 0 |
| Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660826 | 0.013764 | 1.861 | 0 | 0 |
| Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant | R-HSA-2660825 | 0.013764 | 1.861 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.013764 | 1.861 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.013308 | 1.876 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.013332 | 1.875 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.013936 | 1.856 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.014008 | 1.854 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.015155 | 1.819 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.015464 | 1.811 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.015944 | 1.797 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.017841 | 1.749 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.018669 | 1.729 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.020143 | 1.696 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.022539 | 1.647 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.022879 | 1.641 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.023309 | 1.632 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.023700 | 1.625 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.024518 | 1.611 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.025367 | 1.596 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.025428 | 1.595 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.027125 | 1.567 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.027283 | 1.564 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.028130 | 1.551 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.028229 | 1.549 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 0.028229 | 1.549 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 0.031725 | 1.499 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.031725 | 1.499 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.030773 | 1.512 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.031788 | 1.498 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.031251 | 1.505 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.031934 | 1.496 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.034001 | 1.469 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.034001 | 1.469 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 0.034380 | 1.464 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 0.037903 | 1.421 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.037903 | 1.421 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.037903 | 1.421 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.038635 | 1.413 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.036083 | 1.443 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.036476 | 1.438 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.040303 | 1.395 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.041463 | 1.382 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.041603 | 1.381 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.042623 | 1.370 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.042700 | 1.370 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 0.046213 | 1.335 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 0.046213 | 1.335 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 0.046213 | 1.335 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.046431 | 1.333 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.046431 | 1.333 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 0.046431 | 1.333 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.047223 | 1.326 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.047223 | 1.326 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.047486 | 1.323 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.047486 | 1.323 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.047486 | 1.323 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.049251 | 1.308 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.049402 | 1.306 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.049402 | 1.306 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.049928 | 1.302 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.051321 | 1.290 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.055588 | 1.255 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.061807 | 1.209 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.062264 | 1.206 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.062585 | 1.204 | 1 | 1 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.076378 | 1.117 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 0.076378 | 1.117 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.076378 | 1.117 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.076378 | 1.117 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.076378 | 1.117 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.063913 | 1.194 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 0.063913 | 1.194 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 0.063913 | 1.194 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.067904 | 1.168 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.078474 | 1.105 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.071286 | 1.147 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.077394 | 1.111 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.071286 | 1.147 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.063805 | 1.195 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.066959 | 1.174 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 0.063913 | 1.194 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.071276 | 1.147 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.071951 | 1.143 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.067432 | 1.171 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.066134 | 1.180 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.066134 | 1.180 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.075296 | 1.123 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.071214 | 1.147 | 1 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.070227 | 1.153 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.079229 | 1.101 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.077907 | 1.108 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.071286 | 1.147 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 0.079778 | 1.098 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 0.079778 | 1.098 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 0.079778 | 1.098 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.079897 | 1.097 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.079897 | 1.097 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.079897 | 1.097 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.081906 | 1.087 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.082619 | 1.083 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.084387 | 1.074 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.084387 | 1.074 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 0.107150 | 0.970 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 0.107150 | 0.970 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 0.107150 | 0.970 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.107150 | 0.970 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 0.107150 | 0.970 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.202824 | 0.693 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.202824 | 0.693 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.202824 | 0.693 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.202824 | 0.693 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.202824 | 0.693 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 0.111030 | 0.955 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.111030 | 0.955 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.111030 | 0.955 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 0.148862 | 0.827 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.148862 | 0.827 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 0.148862 | 0.827 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 0.148862 | 0.827 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 0.288251 | 0.540 | 0 | 0 |
| t(4;14) translocations of FGFR3 | R-HSA-2033515 | 0.288251 | 0.540 | 0 | 0 |
| Signaling by FGFR3 fusions in cancer | R-HSA-8853334 | 0.288251 | 0.540 | 0 | 0 |
| Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1) | R-HSA-5619096 | 0.288251 | 0.540 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 0.288251 | 0.540 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 0.288251 | 0.540 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 0.288251 | 0.540 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 0.288251 | 0.540 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 0.288251 | 0.540 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.106330 | 0.973 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.106330 | 0.973 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.106330 | 0.973 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.106330 | 0.973 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.130728 | 0.884 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 0.130728 | 0.884 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.093098 | 1.031 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.093098 | 1.031 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.093098 | 1.031 | 0 | 0 |
| Signaling by NOTCH1 HD Domain Mutants in Cancer | R-HSA-2691230 | 0.110763 | 0.956 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD Domain Mutants | R-HSA-2691232 | 0.110763 | 0.956 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.156863 | 0.804 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.156863 | 0.804 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.156863 | 0.804 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 0.229948 | 0.638 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.229948 | 0.638 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.229948 | 0.638 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 0.229948 | 0.638 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 0.364528 | 0.438 | 0 | 0 |
| Defective ABCD1 causes ALD | R-HSA-5684045 | 0.364528 | 0.438 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 0.364528 | 0.438 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 0.364528 | 0.438 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 0.364528 | 0.438 | 0 | 0 |
| Defective F8 sulfation at Y1699 | R-HSA-9674519 | 0.364528 | 0.438 | 0 | 0 |
| Glycogen storage disease type IV (GBE1) | R-HSA-3878781 | 0.364528 | 0.438 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.184435 | 0.734 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.089916 | 1.046 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 0.271599 | 0.566 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.213154 | 0.671 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.213154 | 0.671 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.213154 | 0.671 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.213154 | 0.671 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.139938 | 0.854 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.157407 | 0.803 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.157407 | 0.803 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.157407 | 0.803 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.157407 | 0.803 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.242738 | 0.615 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.242738 | 0.615 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 0.313169 | 0.504 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 0.313169 | 0.504 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 0.313169 | 0.504 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 0.432635 | 0.364 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 0.432635 | 0.364 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 0.432635 | 0.364 | 0 | 0 |
| Defective GSS causes GSS deficiency | R-HSA-5579006 | 0.432635 | 0.364 | 0 | 0 |
| Classical Kir channels | R-HSA-1296053 | 0.432635 | 0.364 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 0.432635 | 0.364 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 0.432635 | 0.364 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 0.432635 | 0.364 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.217021 | 0.663 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.217021 | 0.663 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.159380 | 0.798 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 0.272925 | 0.564 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.272925 | 0.564 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 0.272925 | 0.564 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.272925 | 0.564 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.272925 | 0.564 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.272925 | 0.564 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.272925 | 0.564 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.272925 | 0.564 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.272925 | 0.564 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.194780 | 0.710 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.175477 | 0.756 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.354199 | 0.451 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 0.354199 | 0.451 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 0.354199 | 0.451 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 0.354199 | 0.451 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 0.303471 | 0.518 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.303471 | 0.518 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 0.303471 | 0.518 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.303471 | 0.518 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.265386 | 0.576 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.265386 | 0.576 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.234864 | 0.629 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.165056 | 0.782 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.165056 | 0.782 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.165056 | 0.782 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 0.290274 | 0.537 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 0.334153 | 0.476 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 0.394326 | 0.404 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 0.394326 | 0.404 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 0.493446 | 0.307 | 0 | 0 |
| Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling | R-HSA-2644607 | 0.493446 | 0.307 | 0 | 0 |
| Signaling by LRP5 mutants | R-HSA-5339717 | 0.493446 | 0.307 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 0.493446 | 0.307 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 0.493446 | 0.307 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 0.493446 | 0.307 | 0 | 0 |
| FBXW7 Mutants and NOTCH1 in Cancer | R-HSA-2644605 | 0.493446 | 0.307 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.196867 | 0.706 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.141334 | 0.850 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.276984 | 0.558 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.190208 | 0.721 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.235664 | 0.628 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.364770 | 0.438 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.364770 | 0.438 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.340809 | 0.467 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.433273 | 0.363 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 0.433273 | 0.363 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.433273 | 0.363 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.320461 | 0.494 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.320461 | 0.494 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.150147 | 0.823 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.123522 | 0.908 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.123522 | 0.908 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.123522 | 0.908 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 0.395145 | 0.403 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 0.395145 | 0.403 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.194826 | 0.710 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.286816 | 0.542 | 1 | 1 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.214330 | 0.669 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.366217 | 0.436 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.366217 | 0.436 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.216213 | 0.665 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.260998 | 0.583 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.237693 | 0.624 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.141022 | 0.851 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.322252 | 0.492 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.322252 | 0.492 | 1 | 1 |
| HIV Transcription Initiation | R-HSA-167161 | 0.322252 | 0.492 | 1 | 1 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.322252 | 0.492 | 1 | 1 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.364641 | 0.438 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.364641 | 0.438 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.364641 | 0.438 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.391570 | 0.407 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.391570 | 0.407 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.470832 | 0.327 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 0.470832 | 0.327 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 0.547742 | 0.261 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 0.547742 | 0.261 | 0 | 0 |
| NFE2L2 regulating TCA cycle genes | R-HSA-9818025 | 0.547742 | 0.261 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 0.547742 | 0.261 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 0.547742 | 0.261 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 0.547742 | 0.261 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 0.547742 | 0.261 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 0.547742 | 0.261 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.288916 | 0.539 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.288916 | 0.539 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.288916 | 0.539 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.361793 | 0.442 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.386803 | 0.413 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.358349 | 0.446 | 1 | 1 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.454560 | 0.342 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 0.454560 | 0.342 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.310236 | 0.508 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.371455 | 0.430 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.441722 | 0.355 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 0.506854 | 0.295 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.394766 | 0.404 | 1 | 1 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.483349 | 0.316 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.412993 | 0.384 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.322764 | 0.491 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.259936 | 0.585 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 0.511390 | 0.291 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 0.511390 | 0.291 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.511390 | 0.291 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.541236 | 0.267 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 0.541236 | 0.267 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 0.541236 | 0.267 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 0.596221 | 0.225 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 0.596221 | 0.225 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 0.596221 | 0.225 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 0.596221 | 0.225 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 0.596221 | 0.225 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 0.596221 | 0.225 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 0.596221 | 0.225 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.596221 | 0.225 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 0.596221 | 0.225 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.537544 | 0.270 | 1 | 1 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.537544 | 0.270 | 1 | 1 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.508059 | 0.294 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.510254 | 0.292 | 1 | 1 |
| Lagging Strand Synthesis | R-HSA-69186 | 0.564927 | 0.248 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 0.564927 | 0.248 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.560195 | 0.252 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.560195 | 0.252 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.582229 | 0.235 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.590310 | 0.229 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 0.604865 | 0.218 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.639507 | 0.194 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 0.639507 | 0.194 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 0.639507 | 0.194 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 0.639507 | 0.194 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 0.639507 | 0.194 | 0 | 0 |
| Defective CHST14 causes EDS, musculocontractural type | R-HSA-3595174 | 0.639507 | 0.194 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.603613 | 0.219 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.614716 | 0.211 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.614716 | 0.211 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 0.634077 | 0.198 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 0.634077 | 0.198 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 0.634077 | 0.198 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 0.634077 | 0.198 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 0.634077 | 0.198 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.634077 | 0.198 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 0.638120 | 0.195 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.638120 | 0.195 | 1 | 1 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.638120 | 0.195 | 1 | 1 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 0.638120 | 0.195 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.649973 | 0.187 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.668237 | 0.175 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.660510 | 0.180 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 0.661570 | 0.179 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.661570 | 0.179 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 0.678154 | 0.169 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 0.678154 | 0.169 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.678154 | 0.169 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.678154 | 0.169 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 0.678154 | 0.169 | 0 | 0 |
| FGFR3b ligand binding and activation | R-HSA-190371 | 0.678154 | 0.169 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 0.687375 | 0.163 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 0.687375 | 0.163 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 0.687375 | 0.163 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.687375 | 0.163 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.320422 | 0.494 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.492617 | 0.307 | 1 | 1 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.355847 | 0.449 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.565287 | 0.248 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.460880 | 0.336 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.196987 | 0.706 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.361793 | 0.442 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.265776 | 0.575 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.108332 | 0.965 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 0.217021 | 0.663 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.252389 | 0.598 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.467293 | 0.330 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.173005 | 0.762 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.391570 | 0.407 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.386803 | 0.413 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 0.511390 | 0.291 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.512252 | 0.291 | 1 | 1 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.558300 | 0.253 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.255712 | 0.592 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.649973 | 0.187 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.272925 | 0.564 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.560195 | 0.252 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.635727 | 0.197 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.196867 | 0.706 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.515802 | 0.288 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.265386 | 0.576 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.153109 | 0.815 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.391465 | 0.407 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 0.334153 | 0.476 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.320461 | 0.494 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.366217 | 0.436 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.582229 | 0.235 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 0.129793 | 0.887 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.149421 | 0.826 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 0.213154 | 0.671 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.098909 | 1.005 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.537977 | 0.269 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 0.272925 | 0.564 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.514318 | 0.289 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.582229 | 0.235 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.217021 | 0.663 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.097414 | 1.011 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.171884 | 0.765 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.229948 | 0.638 | 0 | 0 |
| Formation of lateral plate mesoderm | R-HSA-9758920 | 0.229948 | 0.638 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.184435 | 0.734 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.175477 | 0.756 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.158598 | 0.800 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.123330 | 0.909 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.128585 | 0.891 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 0.364770 | 0.438 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.176834 | 0.752 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.425120 | 0.371 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 0.596221 | 0.225 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.480945 | 0.318 | 1 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.555653 | 0.255 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.614716 | 0.211 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.485530 | 0.314 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.101425 | 0.994 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.510254 | 0.292 | 1 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.126135 | 0.899 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.165056 | 0.782 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.614852 | 0.211 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.173005 | 0.762 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.364770 | 0.438 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.489164 | 0.311 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.174456 | 0.758 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.174456 | 0.758 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.192535 | 0.715 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.582735 | 0.235 | 1 | 1 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.268164 | 0.572 | 1 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.093098 | 1.031 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.093098 | 1.031 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.110763 | 0.956 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.093245 | 1.030 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 0.271599 | 0.566 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 0.354199 | 0.451 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.158598 | 0.800 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 0.303471 | 0.518 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.265386 | 0.576 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 0.394326 | 0.404 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 0.493446 | 0.307 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.264307 | 0.578 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.320461 | 0.494 | 1 | 1 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.299871 | 0.523 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 0.634077 | 0.198 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 0.678154 | 0.169 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.682176 | 0.166 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.555653 | 0.255 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.570095 | 0.244 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 0.614716 | 0.211 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.489164 | 0.311 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.290274 | 0.537 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.177399 | 0.751 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.168983 | 0.772 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.175714 | 0.755 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.131695 | 0.880 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 0.506854 | 0.295 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.466345 | 0.331 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.406424 | 0.391 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.511390 | 0.291 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.541236 | 0.267 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.123330 | 0.909 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.538489 | 0.269 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.447285 | 0.349 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.245615 | 0.610 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.495641 | 0.305 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.307512 | 0.512 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 0.188796 | 0.724 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.242738 | 0.615 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.175714 | 0.755 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.128609 | 0.891 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.394326 | 0.404 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.252389 | 0.598 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.433273 | 0.363 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.105952 | 0.975 | 1 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.302672 | 0.519 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.452742 | 0.344 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.541236 | 0.267 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.538604 | 0.269 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 0.634077 | 0.198 | 0 | 0 |
| Synthesis of PIPs in the nucleus | R-HSA-8847453 | 0.678154 | 0.169 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 0.681878 | 0.166 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 0.681878 | 0.166 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.554842 | 0.256 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.203405 | 0.692 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.109657 | 0.960 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.673479 | 0.172 | 1 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 0.441722 | 0.355 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.158598 | 0.800 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.584501 | 0.233 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 0.171452 | 0.766 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.255712 | 0.592 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.132163 | 0.879 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.346870 | 0.460 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 0.541236 | 0.267 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.170627 | 0.768 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.499583 | 0.301 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.435946 | 0.361 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.165368 | 0.782 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.492766 | 0.307 | 1 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.490566 | 0.309 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.101567 | 0.993 | 1 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 0.148862 | 0.827 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 0.148862 | 0.827 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.110763 | 0.956 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.102212 | 0.990 | 0 | 0 |
| Inhibition of nitric oxide production | R-HSA-9636249 | 0.432635 | 0.364 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.334153 | 0.476 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 0.506854 | 0.295 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 0.541236 | 0.267 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.571256 | 0.243 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.510282 | 0.292 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.345317 | 0.462 | 1 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.487481 | 0.312 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.524483 | 0.280 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.521891 | 0.282 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 0.614716 | 0.211 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.516615 | 0.287 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.624119 | 0.205 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.594340 | 0.226 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.198889 | 0.701 | 1 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.271599 | 0.566 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.100304 | 0.999 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.375123 | 0.426 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.511390 | 0.291 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.480340 | 0.318 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.634077 | 0.198 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.634077 | 0.198 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.671174 | 0.173 | 1 | 1 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.451273 | 0.346 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.336916 | 0.472 | 1 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.392886 | 0.406 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.322226 | 0.492 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.668590 | 0.175 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.596397 | 0.224 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.441241 | 0.355 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.542960 | 0.265 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.304430 | 0.517 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.290274 | 0.537 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.575346 | 0.240 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.118941 | 0.925 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.375123 | 0.426 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.587668 | 0.231 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.600795 | 0.221 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.520346 | 0.284 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.299871 | 0.523 | 0 | 0 |
| Formation of editosomes by ADAR proteins | R-HSA-77042 | 0.202824 | 0.693 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.148862 | 0.827 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 0.288251 | 0.540 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 0.288251 | 0.540 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 0.188796 | 0.724 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 0.188796 | 0.724 | 0 | 0 |
| Sensory perception of salty taste | R-HSA-9730628 | 0.229948 | 0.638 | 0 | 0 |
| mRNA Editing: A to I Conversion | R-HSA-75064 | 0.364528 | 0.438 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 0.364528 | 0.438 | 0 | 0 |
| C6 deamination of adenosine | R-HSA-75102 | 0.364528 | 0.438 | 0 | 0 |
| TGFBR3 regulates activin signaling | R-HSA-9839406 | 0.364528 | 0.438 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.150065 | 0.824 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 0.271599 | 0.566 | 0 | 0 |
| Intracellular metabolism of fatty acids regulates insulin secretion | R-HSA-434313 | 0.271599 | 0.566 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.123378 | 0.909 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 0.193818 | 0.713 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 0.193818 | 0.713 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.242738 | 0.615 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.432635 | 0.364 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 0.432635 | 0.364 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.217021 | 0.663 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.130560 | 0.884 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 0.303471 | 0.518 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 0.303471 | 0.518 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.098909 | 1.005 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.209505 | 0.679 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.366217 | 0.436 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.225889 | 0.646 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.322226 | 0.492 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.547742 | 0.261 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 0.454560 | 0.342 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 0.506854 | 0.295 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.506854 | 0.295 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 0.596221 | 0.225 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 0.573917 | 0.241 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 0.590310 | 0.229 | 0 | 0 |
| Agmatine biosynthesis | R-HSA-351143 | 0.639507 | 0.194 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.603613 | 0.219 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.614716 | 0.211 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.615157 | 0.211 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.627588 | 0.202 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.660510 | 0.180 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 0.661570 | 0.179 | 0 | 0 |
| Cysteine formation from homocysteine | R-HSA-1614603 | 0.678154 | 0.169 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.101872 | 0.992 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.095589 | 1.020 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.398123 | 0.400 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.327795 | 0.484 | 1 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.495846 | 0.305 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.382286 | 0.418 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.382286 | 0.418 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.334153 | 0.476 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.308708 | 0.510 | 1 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.300450 | 0.522 | 1 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.391465 | 0.407 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.518915 | 0.285 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.325818 | 0.487 | 1 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 0.490566 | 0.309 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 0.511390 | 0.291 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 0.547742 | 0.261 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.304281 | 0.517 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.644323 | 0.191 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 0.661570 | 0.179 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.525205 | 0.280 | 1 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.245615 | 0.610 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.394326 | 0.404 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 0.639507 | 0.194 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 0.184435 | 0.734 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.194780 | 0.710 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.364770 | 0.438 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.352440 | 0.453 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.603613 | 0.219 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.288916 | 0.539 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.288916 | 0.539 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.256695 | 0.591 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.505612 | 0.296 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.272925 | 0.564 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.272925 | 0.564 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.272925 | 0.564 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 0.334153 | 0.476 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 0.493446 | 0.307 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 0.433273 | 0.363 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.401601 | 0.396 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.678154 | 0.169 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.391465 | 0.407 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 0.433273 | 0.363 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.681878 | 0.166 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 0.313169 | 0.504 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.472570 | 0.326 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.177110 | 0.752 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.366217 | 0.436 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.454560 | 0.342 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.408917 | 0.388 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 0.184435 | 0.734 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.156291 | 0.806 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 0.265386 | 0.576 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.537544 | 0.270 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.175714 | 0.755 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.368334 | 0.434 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.495654 | 0.305 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.594672 | 0.226 | 1 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.165056 | 0.782 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.386980 | 0.412 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 0.288251 | 0.540 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.334153 | 0.476 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 0.493446 | 0.307 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 0.433273 | 0.363 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.470832 | 0.327 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 0.547742 | 0.261 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 0.596221 | 0.225 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.564927 | 0.248 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 0.604865 | 0.218 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 0.604865 | 0.218 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 0.639507 | 0.194 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 0.639507 | 0.194 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.638120 | 0.195 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.644323 | 0.191 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.660510 | 0.180 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.661570 | 0.179 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 0.678154 | 0.169 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.480340 | 0.318 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.615157 | 0.211 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.214525 | 0.669 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.209505 | 0.679 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.450288 | 0.347 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.376538 | 0.424 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.340240 | 0.468 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.283346 | 0.548 | 1 | 1 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.298594 | 0.525 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.681878 | 0.166 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.304860 | 0.516 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.597048 | 0.224 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.612982 | 0.213 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.633394 | 0.198 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.130728 | 0.884 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.657572 | 0.182 | 1 | 1 |
| Ca2+ pathway | R-HSA-4086398 | 0.436349 | 0.360 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.476587 | 0.322 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.518571 | 0.285 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.364770 | 0.438 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.386803 | 0.413 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.452742 | 0.344 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.490566 | 0.309 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.516615 | 0.287 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.492617 | 0.307 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.649973 | 0.187 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.358349 | 0.446 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.564927 | 0.248 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.315566 | 0.501 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.249728 | 0.603 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 0.364770 | 0.438 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.651092 | 0.186 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.398123 | 0.400 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.460880 | 0.336 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 0.364528 | 0.438 | 0 | 0 |
| Regulation of gene expression in endocrine-committed (NEUROG3+) progenitor cells | R-HSA-210746 | 0.271599 | 0.566 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 0.242738 | 0.615 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 0.313169 | 0.504 | 0 | 0 |
| The NLRP1 inflammasome | R-HSA-844455 | 0.432635 | 0.364 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.394326 | 0.404 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 0.493446 | 0.307 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 0.493446 | 0.307 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.235664 | 0.628 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 0.425120 | 0.371 | 0 | 0 |
| Relaxin receptors | R-HSA-444821 | 0.596221 | 0.225 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 0.573917 | 0.241 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 0.639507 | 0.194 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 0.639507 | 0.194 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 0.678154 | 0.169 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.678154 | 0.169 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.537271 | 0.270 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.524728 | 0.280 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.456204 | 0.341 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.375123 | 0.426 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.413610 | 0.383 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 0.687375 | 0.163 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.394326 | 0.404 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.511390 | 0.291 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.684443 | 0.165 | 1 | 1 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.188796 | 0.724 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.173005 | 0.762 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.433273 | 0.363 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.454560 | 0.342 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 0.596221 | 0.225 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 0.596221 | 0.225 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 0.557398 | 0.254 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.634077 | 0.198 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 0.678154 | 0.169 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 0.334153 | 0.476 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 0.425120 | 0.371 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.638120 | 0.195 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.573690 | 0.241 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 0.547742 | 0.261 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 0.596221 | 0.225 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | R-HSA-400511 | 0.687375 | 0.163 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.603475 | 0.219 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 0.547742 | 0.261 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.439048 | 0.357 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 0.590310 | 0.229 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.604865 | 0.218 | 0 | 0 |
| Defective factor VIII causes hemophilia A | R-HSA-9662001 | 0.639507 | 0.194 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.433273 | 0.363 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.489164 | 0.311 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.681878 | 0.166 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.638120 | 0.195 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.688558 | 0.162 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.688558 | 0.162 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.689476 | 0.161 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.689476 | 0.161 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.689476 | 0.161 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.694491 | 0.158 | 1 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.696193 | 0.157 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.700834 | 0.154 | 1 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.700834 | 0.154 | 1 | 1 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.702227 | 0.154 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 0.702227 | 0.154 | 0 | 0 |
| Attachment of bacteria to epithelial cells | R-HSA-9638630 | 0.702227 | 0.154 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.702227 | 0.154 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.705176 | 0.152 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.708647 | 0.150 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.709958 | 0.149 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.710670 | 0.148 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.711540 | 0.148 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.711540 | 0.148 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 0.711540 | 0.148 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.711540 | 0.148 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.711540 | 0.148 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.711540 | 0.148 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.711540 | 0.148 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.711540 | 0.148 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 0.712660 | 0.147 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 0.712660 | 0.147 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.712660 | 0.147 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 0.712660 | 0.147 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.712660 | 0.147 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.712660 | 0.147 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 0.712660 | 0.147 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.716274 | 0.145 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.716274 | 0.145 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.717108 | 0.144 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.717108 | 0.144 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.717108 | 0.144 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.718120 | 0.144 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.721568 | 0.142 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.721568 | 0.142 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.721568 | 0.142 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.721568 | 0.142 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.721568 | 0.142 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.721568 | 0.142 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 0.721568 | 0.142 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.730075 | 0.137 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.731139 | 0.136 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.732144 | 0.135 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.733478 | 0.135 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 0.733478 | 0.135 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 0.734119 | 0.134 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 0.734119 | 0.134 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.734119 | 0.134 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.734119 | 0.134 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 0.734119 | 0.134 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.734119 | 0.134 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.734119 | 0.134 | 0 | 0 |
| Vitamin D (calciferol) metabolism | R-HSA-196791 | 0.734119 | 0.134 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.734119 | 0.134 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.734856 | 0.134 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.739915 | 0.131 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.739915 | 0.131 | 0 | 0 |
| Hypusine synthesis from eIF5A-lysine | R-HSA-204626 | 0.743468 | 0.129 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.743468 | 0.129 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 0.743468 | 0.129 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.743468 | 0.129 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 0.743468 | 0.129 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.743468 | 0.129 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 0.743468 | 0.129 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 0.743468 | 0.129 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 0.743468 | 0.129 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 0.743468 | 0.129 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.743468 | 0.129 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.743468 | 0.129 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 0.743468 | 0.129 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 0.743468 | 0.129 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.745432 | 0.128 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.745705 | 0.127 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 0.755174 | 0.122 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.755174 | 0.122 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 0.755174 | 0.122 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.755174 | 0.122 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 0.755174 | 0.122 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.756334 | 0.121 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.757288 | 0.121 | 1 | 1 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 0.757288 | 0.121 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.757288 | 0.121 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.759155 | 0.120 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.763643 | 0.117 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.764058 | 0.117 | 1 | 1 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.767666 | 0.115 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.769183 | 0.114 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.769379 | 0.114 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.770975 | 0.113 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 0.770975 | 0.113 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 0.770975 | 0.113 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 0.770975 | 0.113 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 0.770975 | 0.113 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 0.770975 | 0.113 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 0.770975 | 0.113 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 0.770975 | 0.113 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 0.770975 | 0.113 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 0.770975 | 0.113 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 0.770975 | 0.113 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 0.770975 | 0.113 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.773711 | 0.111 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.773711 | 0.111 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.773711 | 0.111 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.774199 | 0.111 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 0.774772 | 0.111 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 0.774772 | 0.111 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.774772 | 0.111 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.774772 | 0.111 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.774772 | 0.111 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.774772 | 0.111 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.777632 | 0.109 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.778104 | 0.109 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.778104 | 0.109 | 1 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.778288 | 0.109 | 1 | 1 |
| HIV Transcription Elongation | R-HSA-167169 | 0.778288 | 0.109 | 1 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.778288 | 0.109 | 1 | 1 |
| Aggrephagy | R-HSA-9646399 | 0.778288 | 0.109 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.778912 | 0.109 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.778912 | 0.109 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.781418 | 0.107 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.788019 | 0.103 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.789604 | 0.103 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.789604 | 0.103 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.792985 | 0.101 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 0.792985 | 0.101 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.792985 | 0.101 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.792985 | 0.101 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.792985 | 0.101 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.792985 | 0.101 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.795533 | 0.099 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 0.795533 | 0.099 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 0.795533 | 0.099 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 0.795533 | 0.099 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 0.795533 | 0.099 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 0.795533 | 0.099 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.795533 | 0.099 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 0.795533 | 0.099 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 0.795533 | 0.099 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 0.795533 | 0.099 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.795533 | 0.099 | 0 | 0 |
| Prostanoid ligand receptors | R-HSA-391908 | 0.795533 | 0.099 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.796969 | 0.099 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.797264 | 0.098 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.803819 | 0.095 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.803819 | 0.095 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.804700 | 0.094 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.805534 | 0.094 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.805956 | 0.094 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.808485 | 0.092 | 1 | 1 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.809882 | 0.092 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.809882 | 0.092 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 0.809882 | 0.092 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.809882 | 0.092 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 0.817460 | 0.088 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 0.817460 | 0.088 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 0.817460 | 0.088 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 0.817460 | 0.088 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 0.817460 | 0.088 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 0.817460 | 0.088 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 0.817460 | 0.088 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 0.817460 | 0.088 | 0 | 0 |
| DS-GAG biosynthesis | R-HSA-2022923 | 0.817460 | 0.088 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.817565 | 0.087 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.817565 | 0.087 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 0.817565 | 0.087 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.818625 | 0.087 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.819337 | 0.087 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.819475 | 0.086 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.825538 | 0.083 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.825538 | 0.083 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.825538 | 0.083 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 0.825538 | 0.083 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.825538 | 0.083 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.828495 | 0.082 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.830482 | 0.081 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.830482 | 0.081 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.830482 | 0.081 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.831349 | 0.080 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.832935 | 0.079 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.833150 | 0.079 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.835179 | 0.078 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.836126 | 0.078 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 0.837036 | 0.077 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 0.837036 | 0.077 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 0.837036 | 0.077 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 0.837036 | 0.077 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 0.837036 | 0.077 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 0.837036 | 0.077 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 0.837036 | 0.077 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.837036 | 0.077 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 0.837036 | 0.077 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.839170 | 0.076 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.839459 | 0.076 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.839459 | 0.076 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.839803 | 0.076 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.839927 | 0.076 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.840024 | 0.076 | 0 | 0 |
| ABC transporters in lipid homeostasis | R-HSA-1369062 | 0.840024 | 0.076 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.840024 | 0.076 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 0.840024 | 0.076 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.840024 | 0.076 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.842607 | 0.074 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.842607 | 0.074 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.849417 | 0.071 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.849417 | 0.071 | 1 | 1 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.849668 | 0.071 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.849829 | 0.071 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.851625 | 0.070 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.853410 | 0.069 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 0.853410 | 0.069 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.853410 | 0.069 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.853410 | 0.069 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.853958 | 0.069 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.853958 | 0.069 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.853972 | 0.069 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.853972 | 0.069 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.854514 | 0.068 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.854514 | 0.068 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.854514 | 0.068 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 0.854514 | 0.068 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 0.854514 | 0.068 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 0.854514 | 0.068 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 0.854514 | 0.068 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 0.854514 | 0.068 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.857155 | 0.067 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.860507 | 0.065 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.864613 | 0.063 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 0.864613 | 0.063 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.864613 | 0.063 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 0.865766 | 0.063 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 0.865766 | 0.063 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 0.865766 | 0.063 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 0.865766 | 0.063 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.865766 | 0.063 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.865766 | 0.063 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.868871 | 0.061 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.868871 | 0.061 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 0.870119 | 0.060 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 0.870119 | 0.060 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 0.870119 | 0.060 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.870119 | 0.060 | 0 | 0 |
| Vitamin B2 (riboflavin) metabolism | R-HSA-196843 | 0.870119 | 0.060 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 0.870119 | 0.060 | 0 | 0 |
| Synthesis of IPs in the nucleus | R-HSA-1855191 | 0.870119 | 0.060 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 0.870119 | 0.060 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.874847 | 0.058 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.877159 | 0.057 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.877159 | 0.057 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 0.877159 | 0.057 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.877159 | 0.057 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.877587 | 0.057 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.882046 | 0.055 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 0.882813 | 0.054 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.883057 | 0.054 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.883057 | 0.054 | 0 | 0 |
| Biofilm formation | R-HSA-9931953 | 0.883864 | 0.054 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 0.883864 | 0.054 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.883864 | 0.054 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.884050 | 0.054 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 0.884050 | 0.054 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 0.884050 | 0.054 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.884050 | 0.054 | 0 | 0 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | R-HSA-9837092 | 0.884050 | 0.054 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 0.884050 | 0.054 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 0.884050 | 0.054 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 0.884050 | 0.054 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.884050 | 0.054 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.884050 | 0.054 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.885127 | 0.053 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.886050 | 0.053 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.886050 | 0.053 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.887654 | 0.052 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.887654 | 0.052 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.887654 | 0.052 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.888893 | 0.051 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.888893 | 0.051 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.890915 | 0.050 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.891896 | 0.050 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.892052 | 0.050 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.892542 | 0.049 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.892542 | 0.049 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.893522 | 0.049 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.896379 | 0.048 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.896488 | 0.047 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 0.896488 | 0.047 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.896488 | 0.047 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.896488 | 0.047 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 0.896488 | 0.047 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.896488 | 0.047 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.896488 | 0.047 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 0.896488 | 0.047 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.896488 | 0.047 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.896488 | 0.047 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.896488 | 0.047 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.897311 | 0.047 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.897311 | 0.047 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.898925 | 0.046 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.899288 | 0.046 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.900634 | 0.045 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.900634 | 0.045 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.900785 | 0.045 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.901247 | 0.045 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.901247 | 0.045 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.901490 | 0.045 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.905923 | 0.043 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.906190 | 0.043 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.906190 | 0.043 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.906190 | 0.043 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 0.906190 | 0.043 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.906194 | 0.043 | 1 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.906289 | 0.043 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.906622 | 0.043 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.907438 | 0.042 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.907562 | 0.042 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.907592 | 0.042 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 0.907592 | 0.042 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 0.907592 | 0.042 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 0.907592 | 0.042 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.907592 | 0.042 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 0.907592 | 0.042 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 0.907592 | 0.042 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.907606 | 0.042 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.907606 | 0.042 | 1 | 1 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.907606 | 0.042 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.907966 | 0.042 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.908171 | 0.042 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.913362 | 0.039 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.914008 | 0.039 | 1 | 1 |
| Meiotic synapsis | R-HSA-1221632 | 0.914008 | 0.039 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.914008 | 0.039 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.914008 | 0.039 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.914008 | 0.039 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.914347 | 0.039 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.914770 | 0.039 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 0.917506 | 0.037 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 0.917506 | 0.037 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 0.917506 | 0.037 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 0.917506 | 0.037 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 0.917506 | 0.037 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 0.917506 | 0.037 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 0.917506 | 0.037 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 0.921710 | 0.035 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.921710 | 0.035 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.921833 | 0.035 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.923549 | 0.035 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.924584 | 0.034 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.926099 | 0.033 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.926357 | 0.033 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 0.926357 | 0.033 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 0.926357 | 0.033 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.926357 | 0.033 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 0.926357 | 0.033 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.926357 | 0.033 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 0.926357 | 0.033 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 0.927960 | 0.032 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 0.928700 | 0.032 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 0.928700 | 0.032 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.930901 | 0.031 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.931133 | 0.031 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.932072 | 0.031 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.933399 | 0.030 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.933399 | 0.030 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.934258 | 0.030 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.934258 | 0.030 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 0.934258 | 0.030 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 0.934994 | 0.029 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.934994 | 0.029 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.935409 | 0.029 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.935827 | 0.029 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.936242 | 0.029 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.936594 | 0.028 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.938620 | 0.028 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.938620 | 0.028 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.940432 | 0.027 | 1 | 1 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.940497 | 0.027 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 0.940758 | 0.027 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 0.940758 | 0.027 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 0.941312 | 0.026 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.941312 | 0.026 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 0.941312 | 0.026 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 0.941312 | 0.026 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 0.941312 | 0.026 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 0.941312 | 0.026 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 0.941312 | 0.026 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.941312 | 0.026 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 0.941312 | 0.026 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.943460 | 0.025 | 1 | 1 |
| Macroautophagy | R-HSA-1632852 | 0.943642 | 0.025 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.943861 | 0.025 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.943861 | 0.025 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.943861 | 0.025 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.944734 | 0.025 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.944734 | 0.025 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 0.946035 | 0.024 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.946035 | 0.024 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.946035 | 0.024 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 0.946035 | 0.024 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.946035 | 0.024 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.946197 | 0.024 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.946632 | 0.024 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.946909 | 0.024 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.947498 | 0.023 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.947652 | 0.023 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.947943 | 0.023 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.951236 | 0.022 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.951236 | 0.022 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.952356 | 0.021 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.952497 | 0.021 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 0.953232 | 0.021 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 0.953232 | 0.021 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.955274 | 0.020 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.955274 | 0.020 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.955933 | 0.020 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.955933 | 0.020 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.955933 | 0.020 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.955990 | 0.020 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.957674 | 0.019 | 1 | 1 |
| Potassium Channels | R-HSA-1296071 | 0.957790 | 0.019 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 0.958251 | 0.019 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 0.958251 | 0.019 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 0.958251 | 0.019 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.958251 | 0.019 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 0.958251 | 0.019 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.958862 | 0.018 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.959091 | 0.018 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.959245 | 0.018 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.959305 | 0.018 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 0.959305 | 0.018 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 0.959305 | 0.018 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 0.959305 | 0.018 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.961206 | 0.017 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.961206 | 0.017 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 0.962732 | 0.016 | 0 | 0 |
| Organic anion transport by SLCO transporters | R-HSA-879518 | 0.962732 | 0.016 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 0.962732 | 0.016 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.962881 | 0.016 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 0.962987 | 0.016 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 0.962987 | 0.016 | 0 | 0 |
| Depurination | R-HSA-73927 | 0.962987 | 0.016 | 0 | 0 |
| alpha-linolenic acid (ALA) metabolism | R-HSA-2046106 | 0.962987 | 0.016 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.963138 | 0.016 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.965792 | 0.015 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.965792 | 0.015 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.965792 | 0.015 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.965910 | 0.015 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.966348 | 0.015 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 0.966732 | 0.015 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.966732 | 0.015 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.966732 | 0.015 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 0.966732 | 0.015 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.967504 | 0.014 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.967504 | 0.014 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.969414 | 0.013 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.969414 | 0.013 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 0.969414 | 0.013 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.970303 | 0.013 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 0.970303 | 0.013 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 0.970303 | 0.013 | 0 | 0 |
| Beta-oxidation of pristanoyl-CoA | R-HSA-389887 | 0.970303 | 0.013 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 0.970303 | 0.013 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 0.970303 | 0.013 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 0.970303 | 0.013 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 0.970303 | 0.013 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.970551 | 0.013 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 0.971165 | 0.013 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.971253 | 0.013 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.972102 | 0.012 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 0.972209 | 0.012 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.972209 | 0.012 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.972422 | 0.012 | 0 | 0 |
| Suppression of phagosomal maturation | R-HSA-9637687 | 0.973491 | 0.012 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.973491 | 0.012 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.973491 | 0.012 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 0.973491 | 0.012 | 0 | 0 |
| Linoleic acid (LA) metabolism | R-HSA-2046105 | 0.973491 | 0.012 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.973491 | 0.012 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.973542 | 0.012 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.973542 | 0.012 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.973615 | 0.012 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 0.974757 | 0.011 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 0.974757 | 0.011 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 0.974757 | 0.011 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.975666 | 0.011 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 0.976337 | 0.010 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 0.976337 | 0.010 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 0.976337 | 0.010 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 0.976337 | 0.010 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 0.976337 | 0.010 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 0.976337 | 0.010 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.976477 | 0.010 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 0.977079 | 0.010 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 0.977079 | 0.010 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 0.977079 | 0.010 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 0.977079 | 0.010 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 0.977079 | 0.010 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.977487 | 0.010 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 0.977750 | 0.010 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.978877 | 0.009 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.978877 | 0.009 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.978877 | 0.009 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.978877 | 0.009 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.978877 | 0.009 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.978877 | 0.009 | 0 | 0 |
| Synthesis of very long-chain fatty acyl-CoAs | R-HSA-75876 | 0.979193 | 0.009 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.979193 | 0.009 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.979567 | 0.009 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.979749 | 0.009 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.980912 | 0.008 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.981118 | 0.008 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 0.981118 | 0.008 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 0.981118 | 0.008 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 0.981145 | 0.008 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.981145 | 0.008 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 0.981145 | 0.008 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.981315 | 0.008 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.981522 | 0.008 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.982779 | 0.008 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 0.982869 | 0.008 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.982869 | 0.008 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.982886 | 0.007 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 0.983169 | 0.007 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 0.983169 | 0.007 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.983200 | 0.007 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.983200 | 0.007 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.983200 | 0.007 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.983360 | 0.007 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.983469 | 0.007 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.983469 | 0.007 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.984203 | 0.007 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.984297 | 0.007 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.984330 | 0.007 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.984942 | 0.007 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 0.984977 | 0.007 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.984977 | 0.007 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.985911 | 0.006 | 0 | 0 |
| alpha-linolenic (omega3) and linoleic (omega6) acid metabolism | R-HSA-2046104 | 0.985911 | 0.006 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.986152 | 0.006 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 0.986876 | 0.006 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.986876 | 0.006 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.986876 | 0.006 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.987227 | 0.006 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.987729 | 0.005 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.987995 | 0.005 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.988030 | 0.005 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.988030 | 0.005 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 0.988030 | 0.005 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.988578 | 0.005 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.989196 | 0.005 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 0.989315 | 0.005 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 0.989315 | 0.005 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 0.989511 | 0.005 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.989692 | 0.004 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.989692 | 0.004 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.989895 | 0.004 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.989989 | 0.004 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 0.990463 | 0.004 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.990463 | 0.004 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 0.990463 | 0.004 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 0.990463 | 0.004 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.990463 | 0.004 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 0.990463 | 0.004 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 0.990463 | 0.004 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.990463 | 0.004 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.990498 | 0.004 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.990498 | 0.004 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.990624 | 0.004 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.990827 | 0.004 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.991394 | 0.004 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.991394 | 0.004 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.991410 | 0.004 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.991487 | 0.004 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.991487 | 0.004 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 0.991487 | 0.004 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 0.991487 | 0.004 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.991487 | 0.004 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 0.991487 | 0.004 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 0.991487 | 0.004 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 0.991619 | 0.004 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.991619 | 0.004 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.991767 | 0.004 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.992117 | 0.003 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.992207 | 0.003 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.992402 | 0.003 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 0.992402 | 0.003 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.992402 | 0.003 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.992571 | 0.003 | 1 | 1 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.992616 | 0.003 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.992945 | 0.003 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.992945 | 0.003 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.993010 | 0.003 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.993218 | 0.003 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 0.993218 | 0.003 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 0.993618 | 0.003 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 0.993947 | 0.003 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.993951 | 0.003 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.994222 | 0.003 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.994222 | 0.003 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 0.994222 | 0.003 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.994222 | 0.003 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.994242 | 0.003 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.994299 | 0.002 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.994335 | 0.002 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.994575 | 0.002 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.994597 | 0.002 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.994685 | 0.002 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.994788 | 0.002 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.994788 | 0.002 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.995148 | 0.002 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 0.995152 | 0.002 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.995177 | 0.002 | 1 | 1 |
| Glycogen metabolism | R-HSA-8982491 | 0.995177 | 0.002 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.995271 | 0.002 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.995271 | 0.002 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.995441 | 0.002 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.995441 | 0.002 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.995696 | 0.002 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.995696 | 0.002 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.995696 | 0.002 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 0.995696 | 0.002 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.995723 | 0.002 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 0.996132 | 0.002 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 0.996132 | 0.002 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.996132 | 0.002 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.996158 | 0.002 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.996158 | 0.002 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.996158 | 0.002 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.996158 | 0.002 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 0.996158 | 0.002 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.996287 | 0.002 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.996325 | 0.002 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.996341 | 0.002 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.996433 | 0.002 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.996503 | 0.002 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 0.996503 | 0.002 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.996566 | 0.001 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.996571 | 0.001 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.996759 | 0.001 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.996839 | 0.001 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.996939 | 0.001 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.996939 | 0.001 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.997044 | 0.001 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 0.997268 | 0.001 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.997413 | 0.001 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.997562 | 0.001 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.997562 | 0.001 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.997562 | 0.001 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 0.997562 | 0.001 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 0.997562 | 0.001 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.997668 | 0.001 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.997824 | 0.001 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 0.997824 | 0.001 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.997824 | 0.001 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.998005 | 0.001 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 0.998058 | 0.001 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 0.998058 | 0.001 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.998086 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 0.998097 | 0.001 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 0.998097 | 0.001 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.998097 | 0.001 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.998267 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.998314 | 0.001 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.998418 | 0.001 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 0.998453 | 0.001 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.998453 | 0.001 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.998555 | 0.001 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.998561 | 0.001 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.998564 | 0.001 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.998564 | 0.001 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.998577 | 0.001 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.998619 | 0.001 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 0.998619 | 0.001 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.998691 | 0.001 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.998691 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.998735 | 0.001 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.998768 | 0.001 | 0 | 0 |
| Cytosolic sulfonation of small molecules | R-HSA-156584 | 0.998768 | 0.001 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.998768 | 0.001 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.998816 | 0.001 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.998872 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.998897 | 0.000 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.999016 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 0.999016 | 0.000 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 0.999019 | 0.000 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.999046 | 0.000 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.999124 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.999161 | 0.000 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.999170 | 0.000 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.999188 | 0.000 | 0 | 0 |
| Chondroitin sulfate/dermatan sulfate metabolism | R-HSA-1793185 | 0.999218 | 0.000 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.999244 | 0.000 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.999262 | 0.000 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.999262 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.999263 | 0.000 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.999367 | 0.000 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.999367 | 0.000 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.999385 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 0.999385 | 0.000 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.999385 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.999391 | 0.000 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.999447 | 0.000 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.999498 | 0.000 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.999519 | 0.000 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.999544 | 0.000 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.999549 | 0.000 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.999557 | 0.000 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.999557 | 0.000 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.999593 | 0.000 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.999622 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.999631 | 0.000 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.999648 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 0.999670 | 0.000 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.999712 | 0.000 | 0 | 0 |
| Glycosphingolipid biosynthesis | R-HSA-9840309 | 0.999719 | 0.000 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.999719 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 0.999719 | 0.000 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.999722 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.999729 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.999743 | 0.000 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.999747 | 0.000 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.999747 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 0.999758 | 0.000 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.999801 | 0.000 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.999804 | 0.000 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.999812 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 0.999829 | 0.000 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.999857 | 0.000 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.999859 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.999874 | 0.000 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.999877 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.999880 | 0.000 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.999881 | 0.000 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.999884 | 0.000 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.999884 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 0.999884 | 0.000 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 0.999887 | 0.000 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.999895 | 0.000 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.999897 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 0.999899 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 0.999920 | 0.000 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.999920 | 0.000 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.999924 | 0.000 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.999924 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.999931 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 0.999931 | 0.000 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.999935 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.999938 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 0.999944 | 0.000 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.999948 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 0.999949 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.999950 | 0.000 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.999960 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.999960 | 0.000 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.999967 | 0.000 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.999968 | 0.000 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.999971 | 0.000 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.999971 | 0.000 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.999976 | 0.000 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.999981 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 0.999982 | 0.000 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.999982 | 0.000 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.999983 | 0.000 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.999984 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 0.999984 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.999986 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 0.999991 | 0.000 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.999992 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.999993 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 0.999993 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 0.999994 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.999995 | 0.000 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.999996 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 0.999996 | 0.000 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.999996 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 0.999996 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.999997 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 0.999997 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 0.999998 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.999998 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.999999 | 0.000 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.999999 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.999999 | 0.000 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 1.000000 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 1.000000 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 1.000000 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 1.000000 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.000000 | 0.000 | 1 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 1.000000 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 1.000000 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 1.000000 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000 | 0.000 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 1.000000 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 1.000000 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.000000 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 1.000000 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000 | -0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000 | -0.000 | 1 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | -0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000 | -0.000 | 1 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 1.381089e-10 | 9.860 | 1 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 1.547420e-09 | 8.810 | 1 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 3.729275e-08 | 7.428 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 4.487501e-08 | 7.348 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 2.773166e-07 | 6.557 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 3.826454e-07 | 6.417 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 5.228073e-07 | 6.282 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 8.352037e-07 | 6.078 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 9.493739e-07 | 6.023 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.264114e-06 | 5.898 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.829039e-06 | 5.738 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.047260e-06 | 5.689 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 2.835892e-06 | 5.547 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 3.209076e-06 | 5.494 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 3.659906e-06 | 5.437 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 4.391812e-06 | 5.357 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 5.864855e-06 | 5.232 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 5.864855e-06 | 5.232 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 7.891824e-06 | 5.103 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 1.017089e-05 | 4.993 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.036760e-05 | 4.984 | 1 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.331254e-05 | 4.876 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 1.322086e-05 | 4.879 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 1.624519e-05 | 4.789 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 1.704683e-05 | 4.768 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.202640e-05 | 4.657 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.362545e-05 | 4.627 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 3.159023e-05 | 4.500 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.689921e-05 | 4.433 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 3.872293e-05 | 4.412 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 4.377632e-05 | 4.359 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 4.966277e-05 | 4.304 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 4.966277e-05 | 4.304 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 4.850451e-05 | 4.314 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 5.484151e-05 | 4.261 | 1 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 5.400238e-05 | 4.268 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 5.449631e-05 | 4.264 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 5.658811e-05 | 4.247 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 6.742789e-05 | 4.171 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 7.168404e-05 | 4.145 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 7.251975e-05 | 4.140 | 1 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 7.737480e-05 | 4.111 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 8.294099e-05 | 4.081 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 9.769870e-05 | 4.010 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.056771e-04 | 3.976 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 1.037922e-04 | 3.984 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.080954e-04 | 3.966 | 1 | 1 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.111530e-04 | 3.954 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.120290e-04 | 3.951 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 1.623977e-04 | 3.789 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 2.156534e-04 | 3.666 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 2.123724e-04 | 3.673 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 2.220321e-04 | 3.654 | 1 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 2.245278e-04 | 3.649 | 1 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 2.515582e-04 | 3.599 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.572995e-04 | 3.590 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 2.644408e-04 | 3.578 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 2.710866e-04 | 3.567 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 3.139946e-04 | 3.503 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 3.044397e-04 | 3.516 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 3.044397e-04 | 3.516 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 3.068961e-04 | 3.513 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 3.242850e-04 | 3.489 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 3.244149e-04 | 3.489 | 1 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 4.033648e-04 | 3.394 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 4.099345e-04 | 3.387 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 4.117188e-04 | 3.385 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 4.360454e-04 | 3.360 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 4.712192e-04 | 3.327 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 4.728426e-04 | 3.325 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 4.764790e-04 | 3.322 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 5.380924e-04 | 3.269 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 5.175163e-04 | 3.286 | 1 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 6.228062e-04 | 3.206 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 6.228062e-04 | 3.206 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 6.228062e-04 | 3.206 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 6.228062e-04 | 3.206 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 6.987309e-04 | 3.156 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 7.033086e-04 | 3.153 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 7.494075e-04 | 3.125 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 7.858937e-04 | 3.105 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 8.374998e-04 | 3.077 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 8.588803e-04 | 3.066 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 9.116235e-04 | 3.040 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 9.413523e-04 | 3.026 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 1.013991e-03 | 2.994 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 1.060762e-03 | 2.974 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.077304e-03 | 2.968 | 1 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 1.124684e-03 | 2.949 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 1.154790e-03 | 2.937 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 1.166389e-03 | 2.933 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.196247e-03 | 2.922 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.331541e-03 | 2.876 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.376261e-03 | 2.861 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.379554e-03 | 2.860 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 1.439562e-03 | 2.842 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.454588e-03 | 2.837 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.478604e-03 | 2.830 | 1 | 1 |
| Formation of annular gap junctions | R-HSA-196025 | 1.498491e-03 | 2.824 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 1.498491e-03 | 2.824 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.797303e-03 | 2.745 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.797303e-03 | 2.745 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.845725e-03 | 2.734 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 1.929879e-03 | 2.714 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 2.074518e-03 | 2.683 | 1 | 1 |
| G1 Phase | R-HSA-69236 | 2.046076e-03 | 2.689 | 1 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 2.046076e-03 | 2.689 | 1 | 1 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 2.076994e-03 | 2.683 | 1 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.036642e-03 | 2.691 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.036642e-03 | 2.691 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.117960e-03 | 2.674 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 2.151214e-03 | 2.667 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 2.180451e-03 | 2.661 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 2.180451e-03 | 2.661 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 2.369186e-03 | 2.625 | 1 | 1 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 2.376452e-03 | 2.624 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 2.484910e-03 | 2.605 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 2.484910e-03 | 2.605 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 3.064495e-03 | 2.514 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 2.919847e-03 | 2.535 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 3.068952e-03 | 2.513 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 2.880053e-03 | 2.541 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 2.887082e-03 | 2.540 | 1 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 2.880666e-03 | 2.541 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 3.152886e-03 | 2.501 | 1 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 3.166292e-03 | 2.499 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 3.209793e-03 | 2.494 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 3.463621e-03 | 2.460 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 3.463621e-03 | 2.460 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 3.478460e-03 | 2.459 | 0 | 0 |
| S Phase | R-HSA-69242 | 3.725928e-03 | 2.429 | 1 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 3.907921e-03 | 2.408 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 4.099834e-03 | 2.387 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 4.099834e-03 | 2.387 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 4.276131e-03 | 2.369 | 1 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 4.547223e-03 | 2.342 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 4.629694e-03 | 2.334 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 4.417524e-03 | 2.355 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 4.246172e-03 | 2.372 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 4.633471e-03 | 2.334 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 5.171831e-03 | 2.286 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 5.171831e-03 | 2.286 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 5.177705e-03 | 2.286 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 5.606519e-03 | 2.251 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 5.921974e-03 | 2.228 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 5.939520e-03 | 2.226 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 6.086771e-03 | 2.216 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 6.199781e-03 | 2.208 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 6.362851e-03 | 2.196 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 6.558247e-03 | 2.183 | 1 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 6.863286e-03 | 2.163 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 6.890148e-03 | 2.162 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 6.890148e-03 | 2.162 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 7.237199e-03 | 2.140 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 7.462645e-03 | 2.127 | 1 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 7.853563e-03 | 2.105 | 1 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 7.855129e-03 | 2.105 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 7.855129e-03 | 2.105 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 7.855129e-03 | 2.105 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 7.855129e-03 | 2.105 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 8.144628e-03 | 2.089 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 8.246950e-03 | 2.084 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 8.254147e-03 | 2.083 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 9.880808e-03 | 2.005 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 9.880808e-03 | 2.005 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 9.880808e-03 | 2.005 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 9.880808e-03 | 2.005 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 9.880808e-03 | 2.005 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 9.880808e-03 | 2.005 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 9.526257e-03 | 2.021 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 9.526257e-03 | 2.021 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 9.526257e-03 | 2.021 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 9.234946e-03 | 2.035 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 9.616711e-03 | 2.017 | 1 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 9.415580e-03 | 2.026 | 1 | 1 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 9.526257e-03 | 2.021 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 9.907907e-03 | 2.004 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 1.018919e-02 | 1.992 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 1.041602e-02 | 1.982 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 1.041602e-02 | 1.982 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 1.050025e-02 | 1.979 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 1.052194e-02 | 1.978 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.069412e-02 | 1.971 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 1.135926e-02 | 1.945 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.155399e-02 | 1.937 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.158317e-02 | 1.936 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.246929e-02 | 1.904 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 1.430753e-02 | 1.844 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 1.499242e-02 | 1.824 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 1.567266e-02 | 1.805 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.567266e-02 | 1.805 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 1.567266e-02 | 1.805 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 1.643892e-02 | 1.784 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 1.723478e-02 | 1.764 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects | R-HSA-9632693 | 2.118177e-02 | 1.674 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to p16INK4A Defects | R-HSA-9630750 | 2.118177e-02 | 1.674 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9630794 | 2.118177e-02 | 1.674 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6 | R-HSA-9632700 | 2.118177e-02 | 1.674 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 1.896584e-02 | 1.722 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.896584e-02 | 1.722 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.938348e-02 | 1.713 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.904834e-02 | 1.720 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 2.118177e-02 | 1.674 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.010872e-02 | 1.697 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.896241e-02 | 1.722 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.869216e-02 | 1.728 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 2.014637e-02 | 1.696 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 2.217245e-02 | 1.654 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 2.239739e-02 | 1.650 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 2.268798e-02 | 1.644 | 1 | 1 |
| NRAGE signals death through JNK | R-HSA-193648 | 2.268798e-02 | 1.644 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.277445e-02 | 1.643 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 2.343147e-02 | 1.630 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 2.509860e-02 | 1.600 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.541997e-02 | 1.595 | 1 | 1 |
| Aggrephagy | R-HSA-9646399 | 2.541997e-02 | 1.595 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 2.581643e-02 | 1.588 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 2.623757e-02 | 1.581 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 2.699318e-02 | 1.569 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 2.730826e-02 | 1.564 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 2.763361e-02 | 1.559 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 2.800382e-02 | 1.553 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.827260e-02 | 1.549 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 2.992696e-02 | 1.524 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 3.210136e-02 | 1.493 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 3.210136e-02 | 1.493 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 2.939970e-02 | 1.532 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 3.430721e-02 | 1.465 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 3.103607e-02 | 1.508 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 3.339785e-02 | 1.476 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 3.332609e-02 | 1.477 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 3.310146e-02 | 1.480 | 1 | 1 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.339785e-02 | 1.476 | 1 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.462541e-02 | 1.461 | 1 | 1 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 3.332609e-02 | 1.477 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 3.228345e-02 | 1.491 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 3.103607e-02 | 1.508 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 3.309380e-02 | 1.480 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 3.151905e-02 | 1.501 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 3.151905e-02 | 1.501 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 3.210136e-02 | 1.493 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 3.440630e-02 | 1.463 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.470869e-02 | 1.460 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.555751e-02 | 1.449 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 3.573026e-02 | 1.447 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 3.573026e-02 | 1.447 | 1 | 1 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.588897e-02 | 1.445 | 0 | 0 |
| Regulation of TP53 Expression | R-HSA-6804754 | 3.588897e-02 | 1.445 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.588897e-02 | 1.445 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.588897e-02 | 1.445 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.588897e-02 | 1.445 | 0 | 0 |
| Diseases of Cellular Senescence | R-HSA-9630747 | 3.588897e-02 | 1.445 | 0 | 0 |
| Diseases of cellular response to stress | R-HSA-9675132 | 3.588897e-02 | 1.445 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.588897e-02 | 1.445 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 3.740397e-02 | 1.427 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 3.765062e-02 | 1.424 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 3.850233e-02 | 1.415 | 1 | 1 |
| Signalling to ERKs | R-HSA-187687 | 3.865843e-02 | 1.413 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 3.892453e-02 | 1.410 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 3.892453e-02 | 1.410 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 3.892453e-02 | 1.410 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 3.969313e-02 | 1.401 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 4.142082e-02 | 1.383 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 4.159438e-02 | 1.381 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 4.188055e-02 | 1.378 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 4.254616e-02 | 1.371 | 1 | 1 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 4.254616e-02 | 1.371 | 1 | 1 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 5.346104e-02 | 1.272 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 4.595463e-02 | 1.338 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 4.595463e-02 | 1.338 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 4.556484e-02 | 1.341 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 5.192685e-02 | 1.285 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 4.736728e-02 | 1.325 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 4.770886e-02 | 1.321 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 4.289141e-02 | 1.368 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 5.192685e-02 | 1.285 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 5.322450e-02 | 1.274 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 5.192685e-02 | 1.285 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 4.550050e-02 | 1.342 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 4.406521e-02 | 1.356 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 5.249401e-02 | 1.280 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 5.346104e-02 | 1.272 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 4.595463e-02 | 1.338 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 4.741288e-02 | 1.324 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 5.018259e-02 | 1.299 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 4.788059e-02 | 1.320 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 5.128594e-02 | 1.290 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 4.550050e-02 | 1.342 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 5.387297e-02 | 1.269 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 5.394687e-02 | 1.268 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 5.394687e-02 | 1.268 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.394687e-02 | 1.268 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 5.394687e-02 | 1.268 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 5.519563e-02 | 1.258 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 5.603172e-02 | 1.252 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 5.733777e-02 | 1.242 | 1 | 1 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 5.830706e-02 | 1.234 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 5.845337e-02 | 1.233 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 5.912090e-02 | 1.228 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 5.932865e-02 | 1.227 | 1 | 1 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 5.932865e-02 | 1.227 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 5.974617e-02 | 1.224 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 6.044695e-02 | 1.219 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.044695e-02 | 1.219 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 6.051172e-02 | 1.218 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 6.051172e-02 | 1.218 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 6.051172e-02 | 1.218 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 6.051172e-02 | 1.218 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 6.051172e-02 | 1.218 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 6.193085e-02 | 1.208 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 6.237607e-02 | 1.205 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 6.264149e-02 | 1.203 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 6.264149e-02 | 1.203 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 6.274714e-02 | 1.202 | 1 | 1 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 6.274714e-02 | 1.202 | 1 | 1 |
| HIV Transcription Elongation | R-HSA-167169 | 6.274714e-02 | 1.202 | 1 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 6.274714e-02 | 1.202 | 1 | 1 |
| Extension of Telomeres | R-HSA-180786 | 6.429241e-02 | 1.192 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 6.539131e-02 | 1.184 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 6.612610e-02 | 1.180 | 1 | 1 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 6.612610e-02 | 1.180 | 1 | 1 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 6.612610e-02 | 1.180 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 6.905179e-02 | 1.161 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 6.905179e-02 | 1.161 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 7.117921e-02 | 1.148 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 7.117921e-02 | 1.148 | 0 | 0 |
| Loss of function of TP53 in cancer due to loss of tetramerization ability | R-HSA-9723905 | 7.117921e-02 | 1.148 | 0 | 0 |
| Loss of Function of TP53 in Cancer | R-HSA-9723907 | 7.117921e-02 | 1.148 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 7.203575e-02 | 1.142 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 7.242492e-02 | 1.140 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.299818e-02 | 1.137 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 7.299818e-02 | 1.137 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 7.341632e-02 | 1.134 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 7.341632e-02 | 1.134 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 7.341632e-02 | 1.134 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 7.341632e-02 | 1.134 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 7.341632e-02 | 1.134 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 9.532712e-02 | 1.021 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 9.532712e-02 | 1.021 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 9.532712e-02 | 1.021 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 8.652742e-02 | 1.063 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 8.208236e-02 | 1.086 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 9.278954e-02 | 1.033 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 7.446762e-02 | 1.128 | 1 | 1 |
| HIV Transcription Initiation | R-HSA-167161 | 7.446762e-02 | 1.128 | 1 | 1 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 7.446762e-02 | 1.128 | 1 | 1 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 8.739010e-02 | 1.059 | 1 | 1 |
| mRNA 3'-end processing | R-HSA-72187 | 8.057182e-02 | 1.094 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 8.653080e-02 | 1.063 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 8.461880e-02 | 1.073 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 8.461880e-02 | 1.073 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.250910e-02 | 1.034 | 1 | 1 |
| Polo-like kinase mediated events | R-HSA-156711 | 9.278954e-02 | 1.033 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 8.208236e-02 | 1.086 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 8.643958e-02 | 1.063 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 7.395889e-02 | 1.131 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 9.278954e-02 | 1.033 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 9.278954e-02 | 1.033 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 8.043763e-02 | 1.095 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 7.446762e-02 | 1.128 | 0 | 0 |
| Protein folding | R-HSA-391251 | 8.043763e-02 | 1.095 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 8.077909e-02 | 1.093 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 7.921444e-02 | 1.101 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 9.070073e-02 | 1.042 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 8.923955e-02 | 1.049 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 8.871906e-02 | 1.052 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 8.208236e-02 | 1.086 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 9.278954e-02 | 1.033 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 9.800064e-02 | 1.009 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 9.919796e-02 | 1.003 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.001758e-01 | 0.999 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 1.003116e-01 | 0.999 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.003116e-01 | 0.999 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.003116e-01 | 0.999 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.003116e-01 | 0.999 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 1.010261e-01 | 0.996 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 1.010261e-01 | 0.996 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 1.010261e-01 | 0.996 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 1.010261e-01 | 0.996 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 1.010261e-01 | 0.996 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 1.015015e-01 | 0.994 | 1 | 1 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.021211e-01 | 0.991 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.023042e-01 | 0.990 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 1.023042e-01 | 0.990 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.041220e-01 | 0.982 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.041626e-01 | 0.982 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.041626e-01 | 0.982 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 1.042706e-01 | 0.982 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 1.042706e-01 | 0.982 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.054183e-01 | 0.977 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 1.059026e-01 | 0.975 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 1.089951e-01 | 0.963 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 1.100126e-01 | 0.959 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 1.100126e-01 | 0.959 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.104046e-01 | 0.957 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 1.107330e-01 | 0.956 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 1.116030e-01 | 0.952 | 1 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 1.155947e-01 | 0.937 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 1.160511e-01 | 0.935 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.160511e-01 | 0.935 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 1.164162e-01 | 0.934 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 1.164162e-01 | 0.934 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.164162e-01 | 0.934 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.188145e-01 | 0.925 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 1.188145e-01 | 0.925 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.188145e-01 | 0.925 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 1.188145e-01 | 0.925 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 1.200404e-01 | 0.921 | 1 | 1 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 1.200404e-01 | 0.921 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 1.201496e-01 | 0.920 | 1 | 1 |
| PKR-mediated signaling | R-HSA-9833482 | 1.218280e-01 | 0.914 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 1.248351e-01 | 0.904 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 1.248351e-01 | 0.904 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 1.287274e-01 | 0.890 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 1.372959e-01 | 0.862 | 0 | 0 |
| Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9630791 | 1.372959e-01 | 0.862 | 0 | 0 |
| Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 | R-HSA-9632697 | 1.372959e-01 | 0.862 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 1.372959e-01 | 0.862 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 1.435433e-01 | 0.843 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 1.435433e-01 | 0.843 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 1.435433e-01 | 0.843 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.692184e-01 | 0.772 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 1.692184e-01 | 0.772 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 1.692184e-01 | 0.772 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 1.692184e-01 | 0.772 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 1.326169e-01 | 0.877 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 1.495456e-01 | 0.825 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 1.495456e-01 | 0.825 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 1.671197e-01 | 0.777 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 1.852573e-01 | 0.732 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.852573e-01 | 0.732 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.852573e-01 | 0.732 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 1.307068e-01 | 0.884 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 1.834831e-01 | 0.736 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.891383e-01 | 0.723 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 1.786975e-01 | 0.748 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.711791e-01 | 0.767 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 1.829142e-01 | 0.738 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.348357e-01 | 0.870 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.711791e-01 | 0.767 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.671197e-01 | 0.777 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 1.425146e-01 | 0.846 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 1.326169e-01 | 0.877 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 1.955799e-01 | 0.709 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 1.580791e-01 | 0.801 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.692184e-01 | 0.772 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 1.550953e-01 | 0.809 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.891383e-01 | 0.723 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 1.852573e-01 | 0.732 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 1.852573e-01 | 0.732 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 1.760354e-01 | 0.754 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.647171e-01 | 0.783 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.561788e-01 | 0.806 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.561788e-01 | 0.806 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 1.550953e-01 | 0.809 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.904150e-01 | 0.720 | 1 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 1.842125e-01 | 0.735 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 1.690781e-01 | 0.772 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 1.738240e-01 | 0.760 | 1 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 1.829142e-01 | 0.738 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 1.376345e-01 | 0.861 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 1.430115e-01 | 0.845 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 1.791180e-01 | 0.747 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.856535e-01 | 0.731 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.850623e-01 | 0.733 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 1.407350e-01 | 0.852 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 1.604799e-01 | 0.795 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 1.834831e-01 | 0.736 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.648405e-01 | 0.783 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.900384e-01 | 0.721 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 1.955799e-01 | 0.709 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.430115e-01 | 0.845 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.498288e-01 | 0.824 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 1.326169e-01 | 0.877 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 1.900384e-01 | 0.721 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 1.416664e-01 | 0.849 | 0 | 0 |
| Kinesins | R-HSA-983189 | 1.351252e-01 | 0.869 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 1.382004e-01 | 0.859 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 1.594451e-01 | 0.797 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 1.594451e-01 | 0.797 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 1.415722e-01 | 0.849 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.479883e-01 | 0.830 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.435433e-01 | 0.843 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 1.791180e-01 | 0.747 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 1.692184e-01 | 0.772 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 1.692847e-01 | 0.771 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.900384e-01 | 0.721 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 1.746311e-01 | 0.758 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 1.541833e-01 | 0.812 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 1.779821e-01 | 0.750 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 1.982717e-01 | 0.703 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 1.982717e-01 | 0.703 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.982717e-01 | 0.703 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.985417e-01 | 0.702 | 0 | 0 |
| NFG and proNGF binds to p75NTR | R-HSA-205017 | 1.987098e-01 | 0.702 | 0 | 0 |
| Abasic sugar-phosphate removal via the single-nucleotide replacement pathway | R-HSA-73930 | 1.987098e-01 | 0.702 | 0 | 0 |
| Defective MMADHC causes MMAHCD | R-HSA-3359473 | 1.987098e-01 | 0.702 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 1.987098e-01 | 0.702 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 1.987098e-01 | 0.702 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 1.987098e-01 | 0.702 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 1.987098e-01 | 0.702 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 1.987098e-01 | 0.702 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 1.987098e-01 | 0.702 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 2.012068e-01 | 0.696 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 2.016906e-01 | 0.695 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.016906e-01 | 0.695 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 2.038780e-01 | 0.691 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 2.038780e-01 | 0.691 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 2.038780e-01 | 0.691 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 2.040819e-01 | 0.690 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 2.044905e-01 | 0.689 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 2.087739e-01 | 0.680 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.135597e-01 | 0.670 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 2.147535e-01 | 0.668 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.189925e-01 | 0.660 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 2.218437e-01 | 0.654 | 1 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 2.224004e-01 | 0.653 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 2.224004e-01 | 0.653 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 2.224004e-01 | 0.653 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 2.224004e-01 | 0.653 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 2.224004e-01 | 0.653 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 2.224004e-01 | 0.653 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 2.224004e-01 | 0.653 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 2.224004e-01 | 0.653 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 2.229037e-01 | 0.652 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 2.229037e-01 | 0.652 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 2.229037e-01 | 0.652 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 2.229037e-01 | 0.652 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 2.229037e-01 | 0.652 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 2.557553e-01 | 0.592 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 2.557553e-01 | 0.592 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 2.557553e-01 | 0.592 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 2.557553e-01 | 0.592 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 2.557553e-01 | 0.592 | 0 | 0 |
| Defective MMACHC causes MAHCC | R-HSA-3359474 | 3.087427e-01 | 0.510 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 3.087427e-01 | 0.510 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 3.087427e-01 | 0.510 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 3.087427e-01 | 0.510 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 3.087427e-01 | 0.510 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 3.087427e-01 | 0.510 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 3.087427e-01 | 0.510 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 3.087427e-01 | 0.510 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 3.579606e-01 | 0.446 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 3.579606e-01 | 0.446 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 3.579606e-01 | 0.446 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 3.579606e-01 | 0.446 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 2.494811e-01 | 0.603 | 0 | 0 |
| MAPK3 (ERK1) activation | R-HSA-110056 | 2.494811e-01 | 0.603 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 2.494811e-01 | 0.603 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 2.766492e-01 | 0.558 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 2.766492e-01 | 0.558 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 2.766492e-01 | 0.558 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 2.766492e-01 | 0.558 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 4.036769e-01 | 0.394 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 3.037553e-01 | 0.517 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 3.037553e-01 | 0.517 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 3.037553e-01 | 0.517 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 2.422592e-01 | 0.616 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 2.618724e-01 | 0.582 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 2.618724e-01 | 0.582 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 3.306707e-01 | 0.481 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 3.306707e-01 | 0.481 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 3.306707e-01 | 0.481 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 3.306707e-01 | 0.481 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 3.306707e-01 | 0.481 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 3.306707e-01 | 0.481 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 3.306707e-01 | 0.481 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 3.306707e-01 | 0.481 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 3.306707e-01 | 0.481 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 4.461405e-01 | 0.351 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 4.461405e-01 | 0.351 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 4.461405e-01 | 0.351 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 4.461405e-01 | 0.351 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 4.461405e-01 | 0.351 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 4.461405e-01 | 0.351 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 2.288449e-01 | 0.640 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 3.016010e-01 | 0.521 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 2.604886e-01 | 0.584 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 2.604886e-01 | 0.584 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 2.413778e-01 | 0.617 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 3.215908e-01 | 0.493 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 3.835052e-01 | 0.416 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 2.929011e-01 | 0.533 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 4.092523e-01 | 0.388 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 4.092523e-01 | 0.388 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 4.092523e-01 | 0.388 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 3.615363e-01 | 0.442 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 3.615363e-01 | 0.442 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 3.257940e-01 | 0.487 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 2.850190e-01 | 0.545 | 1 | 1 |
| Deadenylation of mRNA | R-HSA-429947 | 3.813901e-01 | 0.419 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 3.813901e-01 | 0.419 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 3.813901e-01 | 0.419 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 4.344607e-01 | 0.362 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 2.976034e-01 | 0.526 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 3.542157e-01 | 0.451 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 3.542157e-01 | 0.451 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 3.686594e-01 | 0.433 | 1 | 1 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 4.399470e-01 | 0.357 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 4.399470e-01 | 0.357 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 2.797784e-01 | 0.553 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 2.706689e-01 | 0.568 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 4.206347e-01 | 0.376 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 3.456559e-01 | 0.461 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 3.703888e-01 | 0.431 | 1 | 1 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 3.835052e-01 | 0.416 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 4.119396e-01 | 0.385 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.298036e-01 | 0.639 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.331901e-01 | 0.363 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 3.375514e-01 | 0.472 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 4.034574e-01 | 0.394 | 1 | 1 |
| PI3K/AKT activation | R-HSA-198203 | 2.494811e-01 | 0.603 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 4.092523e-01 | 0.388 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 4.344607e-01 | 0.362 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.331901e-01 | 0.363 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 3.306707e-01 | 0.481 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 3.306707e-01 | 0.481 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 2.288449e-01 | 0.640 | 1 | 1 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.771009e-01 | 0.557 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 2.816746e-01 | 0.550 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 4.262431e-01 | 0.370 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 3.302088e-01 | 0.481 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 2.428831e-01 | 0.615 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 2.851335e-01 | 0.545 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.197405e-01 | 0.495 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 3.813981e-01 | 0.419 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 2.766492e-01 | 0.558 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 4.036769e-01 | 0.394 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 4.011033e-01 | 0.397 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.542157e-01 | 0.451 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 3.831075e-01 | 0.417 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.422592e-01 | 0.616 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 2.965760e-01 | 0.528 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 3.572852e-01 | 0.447 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 3.579606e-01 | 0.446 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 3.579606e-01 | 0.446 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 4.461405e-01 | 0.351 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 2.288449e-01 | 0.640 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 3.016010e-01 | 0.521 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 4.119396e-01 | 0.385 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 3.906069e-01 | 0.408 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 4.136600e-01 | 0.383 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.857754e-01 | 0.544 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.816746e-01 | 0.550 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 2.827936e-01 | 0.549 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 2.232019e-01 | 0.651 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 4.206347e-01 | 0.376 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 3.588973e-01 | 0.445 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 3.831075e-01 | 0.417 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 3.857099e-01 | 0.414 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 2.422592e-01 | 0.616 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 4.245473e-01 | 0.372 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 3.787211e-01 | 0.422 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 3.257940e-01 | 0.487 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 3.087427e-01 | 0.510 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 3.087427e-01 | 0.510 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 2.766492e-01 | 0.558 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 4.036769e-01 | 0.394 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 4.036769e-01 | 0.394 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 3.037553e-01 | 0.517 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 3.037553e-01 | 0.517 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 4.461405e-01 | 0.351 | 0 | 0 |
| Ceramide signalling | R-HSA-193681 | 4.461405e-01 | 0.351 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 3.572852e-01 | 0.447 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 4.092523e-01 | 0.388 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 4.092523e-01 | 0.388 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 3.615363e-01 | 0.442 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 3.257940e-01 | 0.487 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 2.406980e-01 | 0.619 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.863633e-01 | 0.543 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 3.454423e-01 | 0.462 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 2.945277e-01 | 0.531 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 2.945277e-01 | 0.531 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 2.515970e-01 | 0.599 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 4.092523e-01 | 0.388 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 4.206347e-01 | 0.376 | 0 | 0 |
| PTK6 Activates STAT3 | R-HSA-8849474 | 4.036769e-01 | 0.394 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 3.016010e-01 | 0.521 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.618724e-01 | 0.582 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 3.787211e-01 | 0.422 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 2.284953e-01 | 0.641 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 3.615363e-01 | 0.442 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 4.142100e-01 | 0.383 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 4.142100e-01 | 0.383 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 4.142100e-01 | 0.383 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 4.036769e-01 | 0.394 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 3.037553e-01 | 0.517 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 3.306707e-01 | 0.481 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 3.306707e-01 | 0.481 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 3.306707e-01 | 0.481 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 4.136600e-01 | 0.383 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 3.016010e-01 | 0.521 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 3.016010e-01 | 0.521 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 4.206347e-01 | 0.376 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 2.604886e-01 | 0.584 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 2.533022e-01 | 0.596 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 4.011033e-01 | 0.397 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.759148e-01 | 0.425 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 2.945277e-01 | 0.531 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 2.429456e-01 | 0.614 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 3.306707e-01 | 0.481 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 3.020450e-01 | 0.520 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 2.738003e-01 | 0.563 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 3.943963e-01 | 0.404 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 3.087427e-01 | 0.510 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 3.579606e-01 | 0.446 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 3.579606e-01 | 0.446 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 4.461405e-01 | 0.351 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 4.344607e-01 | 0.362 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 4.405322e-01 | 0.356 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.397967e-01 | 0.469 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 3.254231e-01 | 0.488 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 3.542157e-01 | 0.451 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 3.615363e-01 | 0.442 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 2.766492e-01 | 0.558 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 3.579606e-01 | 0.446 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 4.461405e-01 | 0.351 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 4.461405e-01 | 0.351 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 3.215908e-01 | 0.493 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 2.550095e-01 | 0.593 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 4.206347e-01 | 0.376 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 2.649477e-01 | 0.577 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 3.321900e-01 | 0.479 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 2.766492e-01 | 0.558 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 4.206347e-01 | 0.376 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 4.036769e-01 | 0.394 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 4.461405e-01 | 0.351 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 3.016010e-01 | 0.521 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 3.835052e-01 | 0.416 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 4.092523e-01 | 0.388 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 4.247647e-01 | 0.372 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 4.410038e-01 | 0.356 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 2.494811e-01 | 0.603 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 3.572852e-01 | 0.447 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 3.423354e-01 | 0.466 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 4.399470e-01 | 0.357 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 4.036769e-01 | 0.394 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 3.306707e-01 | 0.481 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 2.494811e-01 | 0.603 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 3.572852e-01 | 0.447 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 3.626479e-01 | 0.441 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 3.835052e-01 | 0.416 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 3.747367e-01 | 0.426 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 2.391777e-01 | 0.621 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 3.051946e-01 | 0.515 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 2.967014e-01 | 0.528 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 4.547578e-01 | 0.342 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 4.547578e-01 | 0.342 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 4.571042e-01 | 0.340 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 4.571042e-01 | 0.340 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 4.571042e-01 | 0.340 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 4.571042e-01 | 0.340 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 4.571042e-01 | 0.340 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 4.590063e-01 | 0.338 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 4.590063e-01 | 0.338 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 4.590768e-01 | 0.338 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 4.590768e-01 | 0.338 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 4.590768e-01 | 0.338 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 4.590768e-01 | 0.338 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 4.590768e-01 | 0.338 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 4.590768e-01 | 0.338 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 4.590768e-01 | 0.338 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 4.590768e-01 | 0.338 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 4.590768e-01 | 0.338 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 4.590768e-01 | 0.338 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 4.657739e-01 | 0.332 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 4.688497e-01 | 0.329 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 4.720509e-01 | 0.326 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 4.730450e-01 | 0.325 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.733243e-01 | 0.325 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 4.777612e-01 | 0.321 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 4.777823e-01 | 0.321 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 4.777823e-01 | 0.321 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 4.777823e-01 | 0.321 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 4.777823e-01 | 0.321 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 4.830571e-01 | 0.316 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 4.830571e-01 | 0.316 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 4.830571e-01 | 0.316 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 4.830571e-01 | 0.316 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 4.849534e-01 | 0.314 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 4.855826e-01 | 0.314 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 4.855826e-01 | 0.314 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 4.855826e-01 | 0.314 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 4.855826e-01 | 0.314 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 4.855826e-01 | 0.314 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 4.855826e-01 | 0.314 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 4.855826e-01 | 0.314 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 4.855826e-01 | 0.314 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 4.855826e-01 | 0.314 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 4.855826e-01 | 0.314 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 4.855826e-01 | 0.314 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.888066e-01 | 0.311 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 4.962482e-01 | 0.304 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 4.962482e-01 | 0.304 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 4.962482e-01 | 0.304 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 5.008623e-01 | 0.300 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 5.043711e-01 | 0.297 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 5.063674e-01 | 0.296 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 5.063674e-01 | 0.296 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 5.063674e-01 | 0.296 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 5.063674e-01 | 0.296 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 5.063674e-01 | 0.296 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 5.103750e-01 | 0.292 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 5.103785e-01 | 0.292 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 5.143801e-01 | 0.289 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 5.143801e-01 | 0.289 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 5.143801e-01 | 0.289 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 5.152338e-01 | 0.288 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 5.197221e-01 | 0.284 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 5.198344e-01 | 0.284 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 5.198344e-01 | 0.284 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 5.222182e-01 | 0.282 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 5.222182e-01 | 0.282 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 5.222182e-01 | 0.282 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 5.222182e-01 | 0.282 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 5.222182e-01 | 0.282 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 5.222182e-01 | 0.282 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 5.222182e-01 | 0.282 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 5.222182e-01 | 0.282 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 5.222182e-01 | 0.282 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 5.222182e-01 | 0.282 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 5.229932e-01 | 0.282 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 5.262554e-01 | 0.279 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 5.274977e-01 | 0.278 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 5.274977e-01 | 0.278 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 5.289815e-01 | 0.277 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 5.289815e-01 | 0.277 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 5.289815e-01 | 0.277 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 5.289815e-01 | 0.277 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 5.289815e-01 | 0.277 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 5.290587e-01 | 0.276 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 5.313994e-01 | 0.275 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 5.321573e-01 | 0.274 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 5.321573e-01 | 0.274 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 5.358398e-01 | 0.271 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 5.361275e-01 | 0.271 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 5.396331e-01 | 0.268 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 5.418292e-01 | 0.266 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 5.478465e-01 | 0.261 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 5.478465e-01 | 0.261 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 5.495618e-01 | 0.260 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 5.495618e-01 | 0.260 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 5.505244e-01 | 0.259 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 5.508804e-01 | 0.259 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 5.508804e-01 | 0.259 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 5.508804e-01 | 0.259 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 5.508804e-01 | 0.259 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 5.508804e-01 | 0.259 | 0 | 0 |
| ALKBH3 mediated reversal of alkylation damage | R-HSA-112126 | 5.562467e-01 | 0.255 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 5.562467e-01 | 0.255 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 5.562467e-01 | 0.255 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 5.562467e-01 | 0.255 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 5.562467e-01 | 0.255 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 5.562467e-01 | 0.255 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 5.562467e-01 | 0.255 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 5.562467e-01 | 0.255 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 5.562467e-01 | 0.255 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 5.562467e-01 | 0.255 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 5.562467e-01 | 0.255 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 5.640043e-01 | 0.249 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 5.643516e-01 | 0.248 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 5.643516e-01 | 0.248 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 5.643516e-01 | 0.248 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 5.665784e-01 | 0.247 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 5.665784e-01 | 0.247 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 5.720511e-01 | 0.243 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 5.720511e-01 | 0.243 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 5.720511e-01 | 0.243 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 5.720511e-01 | 0.243 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 5.748106e-01 | 0.240 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 5.751891e-01 | 0.240 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 5.751891e-01 | 0.240 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 5.757782e-01 | 0.240 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 5.788088e-01 | 0.237 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 5.831944e-01 | 0.234 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.831944e-01 | 0.234 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 5.841889e-01 | 0.233 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 5.841889e-01 | 0.233 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 5.841889e-01 | 0.233 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 5.846149e-01 | 0.233 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 5.861362e-01 | 0.232 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 5.878535e-01 | 0.231 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 5.878535e-01 | 0.231 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 5.878535e-01 | 0.231 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 5.878535e-01 | 0.231 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 5.878535e-01 | 0.231 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 5.878535e-01 | 0.231 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 5.878535e-01 | 0.231 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 5.878535e-01 | 0.231 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 5.890071e-01 | 0.230 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 5.890071e-01 | 0.230 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 5.924865e-01 | 0.227 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 5.928004e-01 | 0.227 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 5.928004e-01 | 0.227 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 5.945171e-01 | 0.226 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 5.993993e-01 | 0.222 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 5.993993e-01 | 0.222 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 5.993993e-01 | 0.222 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 5.993993e-01 | 0.222 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 5.993993e-01 | 0.222 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 6.014262e-01 | 0.221 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 6.063679e-01 | 0.217 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 6.066049e-01 | 0.217 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 6.066049e-01 | 0.217 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 6.085045e-01 | 0.216 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 6.121837e-01 | 0.213 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 6.121837e-01 | 0.213 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 6.121837e-01 | 0.213 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 6.121837e-01 | 0.213 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 6.121837e-01 | 0.213 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 6.121837e-01 | 0.213 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 6.121837e-01 | 0.213 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 6.136297e-01 | 0.212 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 6.151849e-01 | 0.211 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 6.151849e-01 | 0.211 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 6.172108e-01 | 0.210 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 6.172108e-01 | 0.210 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 6.172108e-01 | 0.210 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 6.172108e-01 | 0.210 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 6.172108e-01 | 0.210 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 6.172108e-01 | 0.210 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 6.172108e-01 | 0.210 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 6.172108e-01 | 0.210 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 6.172108e-01 | 0.210 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 6.172108e-01 | 0.210 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 6.172108e-01 | 0.210 | 0 | 0 |
| Arachidonate production from DAG | R-HSA-426048 | 6.172108e-01 | 0.210 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 6.172108e-01 | 0.210 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 6.172108e-01 | 0.210 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 6.172108e-01 | 0.210 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 6.172108e-01 | 0.210 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 6.305449e-01 | 0.200 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 6.305449e-01 | 0.200 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 6.311443e-01 | 0.200 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 6.311443e-01 | 0.200 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 6.311443e-01 | 0.200 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 6.333387e-01 | 0.198 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 6.333387e-01 | 0.198 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 6.367683e-01 | 0.196 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 6.444787e-01 | 0.191 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 6.444787e-01 | 0.191 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 6.444787e-01 | 0.191 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 6.444787e-01 | 0.191 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 6.444787e-01 | 0.191 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 6.444787e-01 | 0.191 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 6.454749e-01 | 0.190 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 6.454749e-01 | 0.190 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 6.454749e-01 | 0.190 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 6.462570e-01 | 0.190 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 6.462570e-01 | 0.190 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 6.462570e-01 | 0.190 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 6.474729e-01 | 0.189 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 6.493732e-01 | 0.188 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 6.494994e-01 | 0.187 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 6.497281e-01 | 0.187 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 6.516052e-01 | 0.186 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 6.525930e-01 | 0.185 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 6.562677e-01 | 0.183 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 6.588708e-01 | 0.181 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 6.588708e-01 | 0.181 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 6.588708e-01 | 0.181 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.599723e-01 | 0.180 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 6.599723e-01 | 0.180 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 6.626722e-01 | 0.179 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 6.668785e-01 | 0.176 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 6.698056e-01 | 0.174 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 6.698056e-01 | 0.174 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 6.698056e-01 | 0.174 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 6.698056e-01 | 0.174 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 6.698056e-01 | 0.174 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 6.698056e-01 | 0.174 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 6.711770e-01 | 0.173 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 6.740359e-01 | 0.171 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 6.740359e-01 | 0.171 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 6.810498e-01 | 0.167 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 6.820523e-01 | 0.166 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 6.820523e-01 | 0.166 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 6.820523e-01 | 0.166 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 6.831736e-01 | 0.165 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 6.836707e-01 | 0.165 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 6.836707e-01 | 0.165 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 6.843076e-01 | 0.165 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 6.876660e-01 | 0.163 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 6.876660e-01 | 0.163 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 6.876660e-01 | 0.163 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 6.923913e-01 | 0.160 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 6.926247e-01 | 0.160 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 6.933230e-01 | 0.159 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 6.933297e-01 | 0.159 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 6.933297e-01 | 0.159 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 6.933297e-01 | 0.159 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 6.933297e-01 | 0.159 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 6.933297e-01 | 0.159 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 6.933297e-01 | 0.159 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 6.933297e-01 | 0.159 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 6.948593e-01 | 0.158 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 6.948593e-01 | 0.158 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 6.997625e-01 | 0.155 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 6.997625e-01 | 0.155 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 7.136333e-01 | 0.147 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 7.136333e-01 | 0.147 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 7.151686e-01 | 0.146 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 7.151686e-01 | 0.146 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.151686e-01 | 0.146 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 7.151686e-01 | 0.146 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 7.151792e-01 | 0.146 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 7.151792e-01 | 0.146 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 7.151792e-01 | 0.146 | 0 | 0 |
| Interleukin-6 signaling | R-HSA-1059683 | 7.151792e-01 | 0.146 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 7.203220e-01 | 0.142 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 7.228809e-01 | 0.141 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 7.259771e-01 | 0.139 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.299048e-01 | 0.137 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 7.299048e-01 | 0.137 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 7.299048e-01 | 0.137 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 7.299048e-01 | 0.137 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 7.312351e-01 | 0.136 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 7.354731e-01 | 0.133 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 7.354731e-01 | 0.133 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 7.354731e-01 | 0.133 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 7.354731e-01 | 0.133 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 7.354731e-01 | 0.133 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 7.354731e-01 | 0.133 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 7.354731e-01 | 0.133 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 7.354731e-01 | 0.133 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 7.379004e-01 | 0.132 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 7.379004e-01 | 0.132 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 7.439885e-01 | 0.128 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 7.439885e-01 | 0.128 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 7.439885e-01 | 0.128 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 7.464417e-01 | 0.127 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 7.464417e-01 | 0.127 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 7.486328e-01 | 0.126 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 7.494087e-01 | 0.125 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 7.543223e-01 | 0.122 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 7.543223e-01 | 0.122 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 7.543223e-01 | 0.122 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 7.543223e-01 | 0.122 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 7.543223e-01 | 0.122 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 7.543223e-01 | 0.122 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 7.543223e-01 | 0.122 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 7.543223e-01 | 0.122 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 7.543223e-01 | 0.122 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 7.543223e-01 | 0.122 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 7.547457e-01 | 0.122 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 7.574377e-01 | 0.121 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 7.574377e-01 | 0.121 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.574377e-01 | 0.121 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 7.598119e-01 | 0.119 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 7.605083e-01 | 0.119 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 7.605083e-01 | 0.119 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 7.605083e-01 | 0.119 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 7.620894e-01 | 0.118 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 7.628493e-01 | 0.118 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 7.712063e-01 | 0.113 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 7.712063e-01 | 0.113 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 7.712063e-01 | 0.113 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 7.718293e-01 | 0.112 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 7.718293e-01 | 0.112 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 7.718293e-01 | 0.112 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 7.718293e-01 | 0.112 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 7.718293e-01 | 0.112 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 7.718293e-01 | 0.112 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 7.718293e-01 | 0.112 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 7.718293e-01 | 0.112 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 7.718293e-01 | 0.112 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 7.740952e-01 | 0.111 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 7.761194e-01 | 0.110 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 7.784597e-01 | 0.109 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 7.815101e-01 | 0.107 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 7.815101e-01 | 0.107 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 7.825089e-01 | 0.107 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 7.825089e-01 | 0.107 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 7.825089e-01 | 0.107 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 7.825089e-01 | 0.107 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 7.825089e-01 | 0.107 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 7.867066e-01 | 0.104 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 7.880898e-01 | 0.103 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 7.880898e-01 | 0.103 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 7.880898e-01 | 0.103 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 7.880898e-01 | 0.103 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 7.880898e-01 | 0.103 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 7.880898e-01 | 0.103 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 7.932833e-01 | 0.101 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 7.932833e-01 | 0.101 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 7.941700e-01 | 0.100 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 7.941700e-01 | 0.100 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 7.941700e-01 | 0.100 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 8.009681e-01 | 0.096 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 8.009681e-01 | 0.096 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 8.031924e-01 | 0.095 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 8.031924e-01 | 0.095 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 8.031924e-01 | 0.095 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 8.031924e-01 | 0.095 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 8.031924e-01 | 0.095 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 8.039632e-01 | 0.095 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 8.039632e-01 | 0.095 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 8.052747e-01 | 0.094 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 8.052747e-01 | 0.094 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 8.052747e-01 | 0.094 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 8.052747e-01 | 0.094 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 8.052747e-01 | 0.094 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 8.052747e-01 | 0.094 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 8.052747e-01 | 0.094 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 8.080988e-01 | 0.093 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 8.101393e-01 | 0.091 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 8.144034e-01 | 0.089 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 8.153129e-01 | 0.089 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 8.158431e-01 | 0.088 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 8.158431e-01 | 0.088 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 8.172194e-01 | 0.088 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 8.172194e-01 | 0.088 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 8.172194e-01 | 0.088 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 8.172194e-01 | 0.088 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 8.172194e-01 | 0.088 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 8.172194e-01 | 0.088 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 8.172194e-01 | 0.088 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 8.172194e-01 | 0.088 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 8.172194e-01 | 0.088 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 8.177281e-01 | 0.087 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 8.177281e-01 | 0.087 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 8.177281e-01 | 0.087 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 8.189508e-01 | 0.087 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 8.189508e-01 | 0.087 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 8.231858e-01 | 0.085 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 8.258951e-01 | 0.083 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 8.258951e-01 | 0.083 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 8.258951e-01 | 0.083 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 8.258951e-01 | 0.083 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 8.258951e-01 | 0.083 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 8.258951e-01 | 0.083 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 8.258951e-01 | 0.083 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 8.266626e-01 | 0.083 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 8.274118e-01 | 0.082 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 8.302475e-01 | 0.081 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 8.302475e-01 | 0.081 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 8.302475e-01 | 0.081 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 8.302475e-01 | 0.081 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 8.302475e-01 | 0.081 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 8.310693e-01 | 0.080 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 8.331863e-01 | 0.079 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 8.331863e-01 | 0.079 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 8.353307e-01 | 0.078 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 8.354506e-01 | 0.078 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.354506e-01 | 0.078 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 8.355318e-01 | 0.078 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 8.419148e-01 | 0.075 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 8.423478e-01 | 0.075 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 8.423478e-01 | 0.075 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 8.423478e-01 | 0.075 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 8.423478e-01 | 0.075 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 8.423478e-01 | 0.075 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 8.423478e-01 | 0.075 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 8.423478e-01 | 0.075 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 8.423478e-01 | 0.075 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 8.423478e-01 | 0.075 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 8.448810e-01 | 0.073 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 8.450286e-01 | 0.073 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 8.524558e-01 | 0.069 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 8.535861e-01 | 0.069 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 8.535861e-01 | 0.069 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 8.535861e-01 | 0.069 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 8.535861e-01 | 0.069 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 8.535861e-01 | 0.069 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 8.535861e-01 | 0.069 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 8.542827e-01 | 0.068 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 8.579418e-01 | 0.067 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 8.605737e-01 | 0.065 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 8.613338e-01 | 0.065 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 8.613338e-01 | 0.065 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 8.613338e-01 | 0.065 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 8.613338e-01 | 0.065 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 8.640240e-01 | 0.063 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 8.640240e-01 | 0.063 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 8.640240e-01 | 0.063 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 8.640240e-01 | 0.063 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 8.640240e-01 | 0.063 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 8.640240e-01 | 0.063 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 8.640240e-01 | 0.063 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 8.647942e-01 | 0.063 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 8.647942e-01 | 0.063 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 8.690971e-01 | 0.061 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 8.710154e-01 | 0.060 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 8.713539e-01 | 0.060 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 8.730450e-01 | 0.059 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 8.737183e-01 | 0.059 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 8.737183e-01 | 0.059 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 8.737183e-01 | 0.059 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 8.737183e-01 | 0.059 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 8.761622e-01 | 0.057 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 8.764590e-01 | 0.057 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 8.764590e-01 | 0.057 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 8.764590e-01 | 0.057 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.764590e-01 | 0.057 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 8.764999e-01 | 0.057 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 8.776306e-01 | 0.057 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 8.827220e-01 | 0.054 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 8.827220e-01 | 0.054 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 8.834373e-01 | 0.054 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 8.834373e-01 | 0.054 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 8.834643e-01 | 0.054 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 8.836338e-01 | 0.054 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 8.836338e-01 | 0.054 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 8.836338e-01 | 0.054 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 8.844517e-01 | 0.053 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 8.893729e-01 | 0.051 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 8.900490e-01 | 0.051 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 8.910843e-01 | 0.050 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 8.910843e-01 | 0.050 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 8.910843e-01 | 0.050 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 8.910843e-01 | 0.050 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 8.910843e-01 | 0.050 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 8.910843e-01 | 0.050 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 8.910843e-01 | 0.050 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 8.910843e-01 | 0.050 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 8.929113e-01 | 0.049 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 8.953128e-01 | 0.048 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 8.963111e-01 | 0.048 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 8.986120e-01 | 0.046 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 8.988508e-01 | 0.046 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 8.988508e-01 | 0.046 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 8.988508e-01 | 0.046 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 8.988508e-01 | 0.046 | 0 | 0 |
| Defects in cobalamin (B12) metabolism | R-HSA-3296469 | 8.988508e-01 | 0.046 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 8.988508e-01 | 0.046 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 8.988508e-01 | 0.046 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 8.988508e-01 | 0.046 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 8.988508e-01 | 0.046 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 8.988508e-01 | 0.046 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 9.000821e-01 | 0.046 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 9.000962e-01 | 0.046 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 9.012825e-01 | 0.045 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 9.022398e-01 | 0.045 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 9.022398e-01 | 0.045 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 9.022398e-01 | 0.045 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 9.022398e-01 | 0.045 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 9.024270e-01 | 0.045 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.046070e-01 | 0.044 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 9.056862e-01 | 0.043 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 9.060639e-01 | 0.043 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 9.060639e-01 | 0.043 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.078507e-01 | 0.042 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.078507e-01 | 0.042 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 9.106333e-01 | 0.041 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 9.117994e-01 | 0.040 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 9.127630e-01 | 0.040 | 0 | 0 |
| Cobalamin (Cbl) metabolism | R-HSA-9759218 | 9.127630e-01 | 0.040 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 9.127630e-01 | 0.040 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 9.127630e-01 | 0.040 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 9.127630e-01 | 0.040 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.127630e-01 | 0.040 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 9.144288e-01 | 0.039 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.144288e-01 | 0.039 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.181793e-01 | 0.037 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.187739e-01 | 0.037 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.187739e-01 | 0.037 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 9.189848e-01 | 0.037 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 9.189848e-01 | 0.037 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.189848e-01 | 0.037 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 9.224083e-01 | 0.035 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 9.229257e-01 | 0.035 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.229257e-01 | 0.035 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 9.247631e-01 | 0.034 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 9.247631e-01 | 0.034 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 9.247631e-01 | 0.034 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.247631e-01 | 0.034 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 9.247631e-01 | 0.034 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 9.259625e-01 | 0.033 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 9.274116e-01 | 0.033 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.291717e-01 | 0.032 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.301297e-01 | 0.031 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.316502e-01 | 0.031 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 9.330087e-01 | 0.030 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.336025e-01 | 0.030 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 9.349097e-01 | 0.029 | 1 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.351137e-01 | 0.029 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 9.351137e-01 | 0.029 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 9.356537e-01 | 0.029 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 9.376220e-01 | 0.028 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 9.397425e-01 | 0.027 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 9.397425e-01 | 0.027 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.405181e-01 | 0.027 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 9.440414e-01 | 0.025 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 9.440414e-01 | 0.025 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 9.440414e-01 | 0.025 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 9.440414e-01 | 0.025 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.446613e-01 | 0.025 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.453574e-01 | 0.024 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 9.463715e-01 | 0.024 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 9.468997e-01 | 0.024 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 9.479825e-01 | 0.023 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.480338e-01 | 0.023 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.480338e-01 | 0.023 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 9.495495e-01 | 0.022 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.496955e-01 | 0.022 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.517416e-01 | 0.021 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 9.517416e-01 | 0.021 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.517416e-01 | 0.021 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 9.517416e-01 | 0.021 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.517416e-01 | 0.021 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 9.517416e-01 | 0.021 | 0 | 0 |
| Phosphate bond hydrolysis by NUDT proteins | R-HSA-2393930 | 9.517416e-01 | 0.021 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 9.517416e-01 | 0.021 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.517416e-01 | 0.021 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.525474e-01 | 0.021 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.548801e-01 | 0.020 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.551793e-01 | 0.020 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.551850e-01 | 0.020 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.551850e-01 | 0.020 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.551850e-01 | 0.020 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 9.560213e-01 | 0.020 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 9.583829e-01 | 0.018 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.583829e-01 | 0.018 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.583829e-01 | 0.018 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 9.583829e-01 | 0.018 | 0 | 0 |
| CaM pathway | R-HSA-111997 | 9.583829e-01 | 0.018 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.605526e-01 | 0.017 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 9.613529e-01 | 0.017 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 9.613529e-01 | 0.017 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.613529e-01 | 0.017 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 9.613529e-01 | 0.017 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 9.613529e-01 | 0.017 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.613529e-01 | 0.017 | 0 | 0 |
| Depurination | R-HSA-73927 | 9.641110e-01 | 0.016 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.641110e-01 | 0.016 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 9.651515e-01 | 0.015 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 9.658427e-01 | 0.015 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 9.666724e-01 | 0.015 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.666724e-01 | 0.015 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.666724e-01 | 0.015 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 9.672531e-01 | 0.014 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 9.690512e-01 | 0.014 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.690512e-01 | 0.014 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.692324e-01 | 0.014 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 9.695914e-01 | 0.013 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.705559e-01 | 0.013 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 9.706180e-01 | 0.013 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.710905e-01 | 0.013 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.710962e-01 | 0.013 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 9.712603e-01 | 0.013 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.712603e-01 | 0.013 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.712603e-01 | 0.013 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.733119e-01 | 0.012 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 9.733119e-01 | 0.012 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 9.733119e-01 | 0.012 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.733119e-01 | 0.012 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.733119e-01 | 0.012 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 9.733195e-01 | 0.012 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.733933e-01 | 0.012 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 9.744084e-01 | 0.011 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.759284e-01 | 0.011 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.759284e-01 | 0.011 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.769864e-01 | 0.010 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 9.786295e-01 | 0.009 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.786295e-01 | 0.009 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.786295e-01 | 0.009 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.788948e-01 | 0.009 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 9.792237e-01 | 0.009 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.800900e-01 | 0.009 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.801554e-01 | 0.009 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.801554e-01 | 0.009 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.801554e-01 | 0.009 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 9.801888e-01 | 0.009 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.801888e-01 | 0.009 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.804918e-01 | 0.009 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 9.805231e-01 | 0.009 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.814058e-01 | 0.008 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 9.815724e-01 | 0.008 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 9.816765e-01 | 0.008 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.828883e-01 | 0.007 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 9.835743e-01 | 0.007 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 9.836258e-01 | 0.007 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.841104e-01 | 0.007 | 0 | 0 |
| Disease | R-HSA-1643685 | 9.852078e-01 | 0.006 | 1 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.852452e-01 | 0.006 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 9.853469e-01 | 0.006 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.856793e-01 | 0.006 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.856793e-01 | 0.006 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 9.858354e-01 | 0.006 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.862990e-01 | 0.006 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.864804e-01 | 0.006 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.869660e-01 | 0.006 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.872776e-01 | 0.006 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.872776e-01 | 0.006 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.872776e-01 | 0.006 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.875996e-01 | 0.005 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 9.887420e-01 | 0.005 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 9.888481e-01 | 0.005 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 9.891110e-01 | 0.005 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 9.895435e-01 | 0.005 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 9.898140e-01 | 0.004 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.905417e-01 | 0.004 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 9.908232e-01 | 0.004 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.912175e-01 | 0.004 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.918450e-01 | 0.004 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.929689e-01 | 0.003 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 9.929689e-01 | 0.003 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.934714e-01 | 0.003 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.934714e-01 | 0.003 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 9.934714e-01 | 0.003 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 9.934714e-01 | 0.003 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 9.934714e-01 | 0.003 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 9.934714e-01 | 0.003 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 9.934714e-01 | 0.003 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.939380e-01 | 0.003 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.941672e-01 | 0.003 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.943713e-01 | 0.002 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 9.947736e-01 | 0.002 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.949511e-01 | 0.002 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.955089e-01 | 0.002 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.955104e-01 | 0.002 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.957956e-01 | 0.002 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.958162e-01 | 0.002 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.961154e-01 | 0.002 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 9.961903e-01 | 0.002 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.962840e-01 | 0.002 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.966266e-01 | 0.001 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.967688e-01 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.968690e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.970497e-01 | 0.001 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 9.971686e-01 | 0.001 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 9.973193e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.973499e-01 | 0.001 | 0 | 0 |
| Translation | R-HSA-72766 | 9.973901e-01 | 0.001 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.974237e-01 | 0.001 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.975111e-01 | 0.001 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.975197e-01 | 0.001 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.976891e-01 | 0.001 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 9.977233e-01 | 0.001 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.978544e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.982827e-01 | 0.001 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.982827e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.982827e-01 | 0.001 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.982827e-01 | 0.001 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.986374e-01 | 0.001 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.986470e-01 | 0.001 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.988081e-01 | 0.001 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.988153e-01 | 0.001 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.988853e-01 | 0.000 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 9.990958e-01 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.991197e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.992032e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.992551e-01 | 0.000 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.993460e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.993491e-01 | 0.000 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.994831e-01 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.994834e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.995032e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.995091e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.995331e-01 | 0.000 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.995604e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.996391e-01 | 0.000 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.996693e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.996887e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.996890e-01 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 9.997303e-01 | 0.000 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 9.997802e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.997855e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.998152e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.998726e-01 | 0.000 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.998854e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999816e-01 | 0.000 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.999876e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999879e-01 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 9.999893e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999899e-01 | 0.000 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.999902e-01 | 0.000 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.999902e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999927e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999931e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.999952e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999954e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999962e-01 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 9.999969e-01 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 9.999996e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999998e-01 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 9.999999e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 9.999999e-01 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |